EP2054509A2 - Procédé de production d'acides gras polyinsaturés dans des organismes transgéniques - Google Patents

Procédé de production d'acides gras polyinsaturés dans des organismes transgéniques

Info

Publication number
EP2054509A2
EP2054509A2 EP07820931A EP07820931A EP2054509A2 EP 2054509 A2 EP2054509 A2 EP 2054509A2 EP 07820931 A EP07820931 A EP 07820931A EP 07820931 A EP07820931 A EP 07820931A EP 2054509 A2 EP2054509 A2 EP 2054509A2
Authority
EP
European Patent Office
Prior art keywords
acid
fatty acids
fatty acid
desaturase
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07820931A
Other languages
German (de)
English (en)
Inventor
Jörg BAUER
Tom Wetjen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Plant Science GmbH
Original Assignee
BASF Plant Science GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38857863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2054509(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BASF Plant Science GmbH filed Critical BASF Plant Science GmbH
Priority to EP15201721.6A priority Critical patent/EP3066934A1/fr
Priority to EP07820931A priority patent/EP2054509A2/fr
Priority to PL09175508T priority patent/PL2177605T3/pl
Priority to EP09175509.0A priority patent/EP2182056B1/fr
Priority to EP09175508.2A priority patent/EP2177605B1/fr
Publication of EP2054509A2 publication Critical patent/EP2054509A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/02—Other edible oils or fats, e.g. shortenings or cooking oils characterised by the production or working-up
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6432—Eicosapentaenoic acids [EPA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6434—Docosahexenoic acids [DHA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/19—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water (1.14.19)
    • C12Y114/19001—Stearoyl-CoA 9-desaturase (1.14.19.1), i.e. DELTA9-desaturase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y602/00—Ligases forming carbon-sulfur bonds (6.2)
    • C12Y602/01—Acid-Thiol Ligases (6.2.1)
    • C12Y602/01003—Long-chain-fatty-acid-CoA ligase (6.2.1.3)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
    • Y02A40/81—Aquaculture, e.g. of fish
    • Y02A40/818—Alternative feeds for fish, e.g. in aquacultures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Definitions

  • the present invention relates to polynucleotides from Ostreococcus lucimarinus which encode desaturases and elongases and can be used for the recombinant production of polyunsaturated fatty acids. Furthermore, the invention relates to vectors, host cells and transgenic non-human organisms containing the polynucleotides, as well as the polypeptides encoded by the polynucleotides. Finally, the invention also relates to production processes for the polyunsaturated fatty acids and for oil, lipid and fatty acid compositions.
  • Fatty acids and triacylglycerides have a variety of uses in the food, animal nutrition, cosmetics and pharmaceutical industries. Depending on whether they are free saturated and unsaturated fatty acids or triacylglycerides with an increased content of saturated or unsaturated fatty acids, they are suitable for a wide variety of applications.
  • Polyunsaturated fatty acids such as linoleic and linolenic acid are essential for mammals because they can not be produced by them. Therefore, polyunsaturated ⁇ -3 fatty acids and ⁇ -6 fatty acids are an important component of animal and human food.
  • polyunsaturated ⁇ -3 fatty acids which are preferred in fish oils, is particularly important for food.
  • the unsaturated fatty acid DHA is thereby attributed a positive effect on the development and maintenance of brain functions.
  • polyunsaturated fatty acids are referred to as PUFA, PUFAs, LCPUFA or LCPUFAs (poly unsaturated fatty acids, PUFA, polyunsaturated fatty acids, long chain poly unsaturated fatty acids, LCPUFA, long-chain polyunsaturated fatty acids).
  • the free fatty acids are advantageously prepared by saponification.
  • Common natural sources of these fatty acids are fish such as herring, salmon, sardine, perch, eel, carp, trout, halibut, mackerel, zander or tuna or algae.
  • oils with saturated or unsaturated fatty acids are preferred.
  • lipids with unsaturated fatty acids especially polyunsaturated fatty acids
  • the polyunsaturated ⁇ -3 fatty acids thereby a positive effect on the cholesterol level in the blood and thus the possibility of preventing heart disease is attributed.
  • ⁇ -3 fatty acids By adding these ⁇ -3 fatty acids to the diet, the risk of heart disease, stroke or hypertension can be significantly reduced.
  • inflammatory especially chronic inflammatory processes in the context of immunological diseases such as rheumatoid arthritis can be positively influenced by ⁇ -3 fatty acids. They are therefore added to foods especially dietary foods or found in medicines application.
  • ⁇ -6 fatty acids such as arachidonic acid tend to have a negative effect on these diseases in these rheumatic diseases due to our usual food composition.
  • ⁇ -3- and ⁇ -6 fatty acids are precursors of tissue hormones, the so-called eicosanoids such as the prostaglandins derived from dihomo- ⁇ -linolenic acid, arachidonic acid and eicosapentaenoic acid, the thromoxanes and leukotrienes derived from arachidonic acid and Derive the eicosapentaenoic acid.
  • Eicosanoids (so-called PG 2 series), which are formed from ⁇ -6 fatty acids promote in the Usually inflammatory reactions, while eicosanoids (so-called PG3 series) of ⁇ -3 fatty acids have little or no proinflammatory effect.
  • ⁇ -6 desaturases are described in WO 93/06712, US Pat. No. 5,614,393, US Pat. No. 5,614,393, WO 96/21022, WO00 / 21557 and WO 99/2711 1 and also the application for production in transgenic organisms as described in WO98 / 46763 WO98 / 46764, WO9846765.
  • the expression of various desaturases as described in WO99 / 64616 or WO98 / 46776 and formation of polyunsaturated fatty acids is also described and claimed. Concerning.
  • microorganisms for the production of PUFAs are microorganisms such as microalgae such as Phaeodactylum tricornutum, Porphiridium species, Thraustochytria species, Schizochytria species or Crypthecodinium species, ciliates such as Stylonychia or Colpidium, fungi such as Mortierella, Entomophthora or Mucor and / or mosses such as Physcomitrella, Ceratodon and Marchantia (R. Vazhappilly & F. Chen (1998) Botanica Marina 41: 553-558; K. Totani & K. Oba (1987) Lipids 22: 1060-1062; Akimoto, M.
  • microalgae such as Phaeodactylum tricornutum, Porphiridium species, Thraustochytria species, Schizochytria species or Crypthecodinium species, ciliates such as Stylonychia or Colpidium
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • Chain length - instead of the ⁇ 4-desaturation, a further elongation step at 24 C, a further ⁇ 6-desaturation and finally beta-oxidation to the C 22 is carried out here.
  • the so-called spokesman synthesis route is not suitable because the regulatory mechanisms are not known.
  • the polyunsaturated fatty acids can be divided according to their desaturation pattern into two major classes, ⁇ -6 or ⁇ -3 fatty acids, which have metabolically and functionally different activities.
  • the starting material for the ⁇ -6 pathway is the fatty acid linoleic acid (18: 2 ⁇ 9 12 ), while the ⁇ -3 pathway is via linolenic acid (18: 3 ⁇ 9 12 / I5 ).
  • Linolenic acid is formed by the activity of an ⁇ -3-desaturase (Tocher et al., 1998, Prog. Lipid Res., 37, 73-117, Domergue et al., 2002, Eur. J. Biochem., 269, 4105-4113). Mammals, and therefore also humans, have no corresponding desaturase activity ( ⁇ -12 and ⁇ -3-desaturase) and must ingest these fatty acids (essential fatty acids) through the diet.
  • the elongation of fatty acids by elongases by 2 or 4 C atoms is of crucial importance for the production of C 2 O or C 22 PUFAs.
  • This process runs over 4 stages.
  • the first step is the condensation of malonyl-CoA on the fatty acyl-CoA by ketoacyl-CoA synthase (KCS, hereinafter referred to as elongase).
  • KCS ketoacyl-CoA synthase
  • KCR ketoacyl-CoA reductase
  • dehydratase dehydration step
  • enoyl-CoA reductase enoyl-CoA reductase
  • Higher plants contain polyunsaturated fatty acids such as linoleic acid (C18: 2) and linolenic acid (C18: 3).
  • ARA, EPA and DHA are absent or only found in the seed oil of higher plants (E. Ucciani: Germany Dictionnaire des Huiles Vegetales, Technique & Documentation - Lavoisier, 1995. ISBN: 2-7430-0009-0).
  • oilseeds such as oilseed rape, linseed, sunflower and soybeans, as this will enable large quantities of high quality LCPUFAs to be obtained inexpensively for the food, animal and pharmaceutical industries.
  • gene coding for enzymes of biosynthesis must be advantageous via genetic engineering methods introduced and expressed by LCPUFAs in oilseeds.
  • These genes can be advantageously isolated from microorganisms and lower plants that produce LCPUFAs and incorporate them into the membranes or triacylglycerides.
  • ⁇ 6-desaturase genes from the moss Physcomitrella patens and ⁇ 6 elongase genes from P. patens and the nematode C. elegans have been isolated.
  • the present invention thus relates to a polynucleotide comprising a nucleic acid sequence which is selected from the group consisting of:
  • nucleic acid sequence encoding a polypeptide having an amino acid sequence as in any one of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14 or 16;
  • nucleic acid sequence encoding a polypeptide that is at least 70% identical to a polypeptide encoded by the nucleic acid sequences of (a) or (b), the polypeptide having desaturase or elongase activity; and (d) a nucleic acid sequence for a fragment of a nucleic acid of (a), (b) or (c), wherein the fragment encodes a polypeptide having a desaturase or elongase activity.
  • polynucleotide relates to polynucleotides comprising nucleic acid sequences encoding polypeptides having desaturase or elongase activity.
  • the desaturase or elongase activities are preferably required for the biosynthesis of lipids or fatty acids. Particularly preferred are the following desaturase or elongase activities: ⁇ -4-desaturase, ⁇ -5-desaturase, ⁇ -5 elongase, ⁇ -6-desaturase, ⁇ -6 elongase or ⁇ -12-desaturase.
  • the desaturases and / or elongases are preferably involved in the synthesis of polyunsaturated fatty acids (PUFAs) and more preferably in the synthesis of long-chain PUFAs (LCPUFAs).
  • PUFAs polyunsaturated fatty acids
  • LCPUFAs long-chain PUFAs
  • Suitable detection systems for these desaturase or elongase activities are described in the examples or in WO2005 / 083053. With regard to substrate specificities and conversion rates, the abovementioned activities are particularly preferably those of the respective enzymes from Ostereococcus lucimarinus.
  • the specific polynucleotides of the invention i. the polynucleotides having a nucleic acid sequence according to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13 or 15 were obtained from Ostereococcus lucimarinus.
  • polynucleotides according to the invention are:
  • Polynucleotides which encode a polypeptide having ⁇ -12-desaturase activity and (i) comprise a nucleic acid sequence as shown in SEQ ID NO: 1 or 3, (ii) a nucleic acid sequence encoding a polypeptide as in SEQ ID NO: 2 or 4, (iii) comprise a nucleic acid sequence which is at least 83% identical to any of the nucleic acid sequences of (i) or (ii), or (iv) a nucleic acid sequence of a fragment of a nucleic acid of (i), (ii ) or (iii).
  • Polynucleotides which encode a polypeptide having ⁇ -4-desaturase activity and (i) comprise a nucleic acid sequence as shown in SEQ ID NO: 5, (ii) comprise a nucleic acid sequence coding for a polypeptide as shown in SEQ ID NO: 6, (iii) comprise a nucleic acid sequence which is at least 72% identical to one of the nucleic acid sequences of (i) or (ii), or (iv) a nucleic acid sequence of a fragment of a nucleic acid of (i), (ii) or (iii).
  • Polynucleotides encoding a ⁇ 5-desaturase activity polypeptide (i) a
  • Nucleic acid sequence comprise, as shown in SEQ ID NO: 7 or 9, (ii) a nucleic acid sequence encoding a polypeptide as in SEQ ID NO: 8 or 10 (iii) comprise a nucleic acid sequence which is at least 72% identical to any one of the nucleic acid sequences of (i) or (ii), or (iv) a nucleic acid sequence of a fragment of a nucleic acid of (i), (ii) or (iii) ,
  • Polynucleotides which encode a ⁇ 5-elongase activity polypeptide and comprise a nucleic acid sequence as shown in SEQ ID NO: 11, (ii) comprise a nucleic acid sequence encoding a polypeptide as shown in SEQ ID NO: 12, (iii) comprise a nucleic acid sequence at least 78% identical to any one of the nucleic acid sequences of (i) or (ii), or (iv) a nucleic acid sequence of a nucleic acid fragment of (i), (ii) or (iii ).
  • Polynucleotides which encode a polypeptide having ⁇ -6-desaturase activity and (i) comprise a nucleic acid sequence as shown in SEQ ID NO: 13, (ii) comprise a nucleic acid sequence which codes for a polypeptide as shown in SEQ ID NO: 14, (iii) comprise a nucleic acid sequence which is at least 72% identical to any one of the nucleic acid sequences of (i) or (ii), or (iv) a nucleic acid sequence of a fragment of a nucleic acid of (i), (ii) or (iii ).
  • polynucleotide also encompasses variants of the aforementioned specific polynucleotides. These may be homologs, orthologues or paralogue sequences. Such varainates comprise nucleic acid sequences which have at least one base exchange, one base addition or one base deletion, wherein the variants should still encode a polypeptide having the aforementioned biological activity of the respective starting sequence.
  • Varieties include polynucleotides that can hybridize with the aforementioned polynucleotides, preferably under stringent conditions. Particularly preferred stringent conditions are known in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1-6.3.6.
  • a preferred example of stringent hybridization conditions are hybridizations in 6x sodium chloride / sodium citrate (SSC) at about 45 ° C, followed by one or more washes in 0.2x SSC, 0.1% SDS at 50-65 ° C. It is known to those skilled in the art that these hybridization conditions differ with respect to the type of nucleic acid and, for example, when organic solvents are present, with respect to the temperature and the concentration of the buffer. The temperature differs, for example under "standard hybridization conditions" depending on the type of nucleic acid between 42 ° C and 58 ° C in aqueous buffer with a concentration of 0.1 to 5 x SSC (pH 7.2).
  • the temperature is about 42 ° C under standard conditions.
  • the hybridization conditions for DNA: DNA hybrids are, for example, 0.1 x SSC and 20 0 C to 45 ° C, preferably between 30 0 C and 45 ° C.
  • the hybridization conditions for DNA: RNA hybrids are, for example, 0.1 x SSC and 30 0 C to 55 ° C, preferably between 45 ° C and 55 ° C.
  • conserveed sequences can be determined by sequence comparisons with polynucleotides encoding polypeptides of similar activity.
  • DNA or cDNA from bacteria, fungi, plants or animals can be used as a template.
  • DNA fragments obtained by the PCR can be used to screen appropriate genomic or cDNA libraries to isolate, if necessary, the complete open reading frame of the polynucleotide and to determine by sequencing.
  • Other variants include polynucleotides comprising a nucleic acid sequence comprising at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%.
  • At least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%, or at any other percentage referred to herein, is identical to any one of the aforementioned specific nucleic acid sequences and a polypeptide encodes the particular biological activity.
  • polypeptide having an amino acid sequence comprising nucleic acid sequences encoding a polypeptide having an amino acid sequence, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% or at any other percentage referred to herein is identical to one of aforementioned specific amino acid sequences and wherein the polypeptide has the respective biological activity of the starting sequence.
  • the percentage of identical nucleotides or amino acids preferably refers to a sequence segment of at least 50% of the sequences to be compared and most preferably the full length of the sequences to be compared.
  • a variety of programs that implement algorithms for such comparisons are known in the art and commercially available. In particular, reference is made to the algorithms of Needleman and Wunsch or Smith and Waterman, which provide particularly reliable results. These algorithms may preferably be implemented by the following programs: PiIeUp (J. Mol. Evolution., 25, 351-360, 1987, Higgins et al., CABIOS, 5 1989: 151-153), Gap and Bestfit (Needleman and Wunsch Biol. 48: 443-453 (1970)) and Smith and Waterman (Adv. Appl. Math.
  • the percentage (%) of sequence identity within the scope of the present invention is determined with the GAP program over the entire sequence with the following fixed sizes: Gap Weight: 50, Length Weight: 3, Average Match: 10,000, and Average Mismatch: 0.000.
  • a polynucleotide comprising only a fragment of the aforementioned nucleic acid sequences is also a polynucleotide of the invention.
  • the fragment is intended to encode a polypeptide which has the biological activity of the starting sequence or of the polypeptide encoded therefrom.
  • Polypeptides encoded by such polynucleotides therefore comprise or consist of domains of the aforementioned specific polypeptides (parent polypeptides) which mediate biological activity.
  • a fragment according to the invention preferably comprises at least 50, at least 100, at least 250 or at least 500 consecutive nucleotides of the abovementioned specific sequences or encodes an amino acid sequence comprising at least 20, at least 30, at least 50, at least 80, at least 100, or at least 150 consecutive amino acids of any one of the aforementioned specific amino acid sequences.
  • polynucleotide variants of the invention preferably have at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the respective biological activity of the polypeptide is encoded by the starting sequence.
  • polypeptides encoded by the polynucleotides of the invention may be involved in the metabolism of compounds necessary for building fatty acids, fatty acid esters such as di-glycylglycerides and / or triacylglycerides in an organism, preferably in a plant or plant cell, or transporting molecules through membranes participate, wherein Ci ⁇ -, C 2 0 or C 22 carbon chains in the fatty acid molecule with double bonds at least two, preferably three, four, five or six positions are meant.
  • the polynucleotides of the invention either comprise or consist of the aforementioned specific nucleic acid sequences. That is to say, the polynucleotides according to the invention may in principle also comprise further nucleotides. These may preferably be 3 ' or 5 ' untranslated regions of the genomic nucleic acid sequence. These preferably consist of at least 100, 200 or 500 nucleotides at the 5 'terminus and at least 20, 50 or 100 nucleotides at the 3' terminus of the coding region.
  • Other polynucleotides comprising additional nucleic acid sequences are those encoding fusion proteins. Such fusion proteins may further encode polypeptide or polypeptide portions in addition to the aforementioned polypeptides.
  • the additional polypeptide or polypeptide portion may be other enzymes of lipid or fatty acid biosynthesis.
  • polypeptides which can serve as markers for expression green, yellow, red, blue-fluorescent proteins, alkaline phosphatase, etc.
  • tags as markers or aid for purification (eg FLAG tags , 6-histidine tags, MYC tags, etc.).
  • Polynucleotide variants can be isolated from a variety of natural or artificial sources. For example, they can be generated artificially by in vitro or in vivo mutagenesis. Homologs or orthologues of the specific sequences can be obtained from a wide variety of animals, plants or microorganisms. Preferably, they are obtained from algae.
  • algae of the family Prasinophyceae as from the genera Heteromastix, Mammiella, Mantoniella, Micromonas, Nephroselmis, Ostreococcus, Prasinocladus, Prasinococcus, Pseudoscourfielda, Pycnococcus, Pyramimonas, Scherffelia or Tetraselmis as the genera and species Heteromastix longifillis, Mamiella gilva, Mantoniella squama- ta, Micromona pusilla, Nephroselmis olivacea, Nephroselmis pyriformis, Nephroselmis rotunda, Ostreococcus tauri, Ostreococcus sp.
  • the polynucleotides are derived from algae of the genera Mantonielle or Ostreococcus.
  • algae such as Isochrysis or Crypthecodinium
  • algae / diatoms such as Thalassiosira, Phaeodactylum or Thraustochytrium
  • mosses such as Physcomitrella or Ceratodon
  • algae of the genera Mantonielle or Ostreococcus or the diatoms of the genera Thalassiosira or Crypthecodinium most preferably the algae of the genera Mantonielle or Ostreococcus or the diatoms of the genera Thalassiosira or Crypthecodinium.
  • the polynucleotides may also preferably be obtained from higher plants such as the primulaceae such as Aleuritia, Calendula stellata, Osteospermum spinescens or Osteospermum hyoseroides, microorganisms such as fungi such as Aspergillus, Thraustochytrium, Phytophthora, Entomophthora, Mucor or Mortierella, bacteria such as Shewanella, yeasts or animals such as Nematodes eg Caenorhabditis, insects or fish.
  • the polynucleotide variants are also preferably derived from an animal of the vertebrate order.
  • the polynucleotides are of the vertebrate class; Euteleostomi, Actinopterygii; Neopterygii; Teleostei; Euteleostei, Protacanthopterygii, Salmoniformes; Salmonidae or Oncorhynchus and, most preferably, from the order of Salmoniformes such as the family Salmonidae such as the genus Salmo, for example, from the genera and species Oncorhynchus mykiss, Trutta trutta or Salmo trutta fario.
  • the polynucleotides according to the invention can in this case be isolated by means of standard molecular biological techniques and the sequence information provided here.
  • a homologous sequence or homologous, conserved sequence regions at the DNA or amino acid level can be identified. These may be used as a hybridization probe as well as standard hybridization techniques (such as described in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., CoId Spring Harbor Laboratory, ColD Spring Harbor Laboratory Press, ColD Spring Harbor, NY, 1989) Isolation of other useful in the process of nucleic acid sequences can be used.
  • polynucleotides or fragments thereof can be isolated by polymerase chain reaction (PCR) using oligonucleotide primers based on this sequence or portions thereof (eg, a nucleic acid molecule comprising the complete sequence or a portion thereof can be polymerase chain-reaction utilized isolated from oligonucleotide primers prepared on the basis of this same sequence).
  • PCR polymerase chain reaction
  • mRNA can be isolated from cells (eg, by the guanidinium thiocyanate extraction method of Chirgwin et al.
  • oligonucleotide primers for amplification by polymerase chain reaction can be prepared on the basis of the amino acid sequences shown in the SEQ ID numbers.
  • a nucleic acid of the invention may be amplified using cDNA or alternatively genomic DNA as a template and suitable oligonucleotide primers according to standard PCR amplification techniques.
  • the thus amplified nucleic acid can be cloned into a suitable vector and characterized by DNA sequence analysis.
  • Oligonucleotides corresponding to a desaturase nucleotide sequence can be prepared by standard synthetic methods, for example with an automated DNA synthesizer.
  • the polynucleotides of the invention may be provided either as isolated polynucleotides (i.e., isolated from their natural origin, e.g., the genomic locus) or in genetically altered form (i.e., the polynucleotides may also be present at their natural genetic locus, but must then be genetically engineered).
  • An isolated polynucleotide preferably comprises less than 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleic acid sequence naturally present in its vicinity.
  • the polynucleotide according to the invention can be in the form of a single-stranded or double-stranded nucleic acid molecule and can be genomic DNA, cDNA or RNA.
  • the polynucleotides of the invention include all orientations of the sequences shown in the SEQ ID Nos., I. also complementary strands and reverse or reverse-complementary orientations. Further, the term also includes chemically modified nucleic acids, such as the naturally occurring methylated DNA molecules, or artificial nucleic acids, e.g. biotinylated nucleic acids.
  • the invention also encompasses oligonucleotides of at least 15 bp, preferably at least 20 bp, at least 25 bp, at least 30 bp, at least 35 bp, or at least 50 bp, which can specifically hybridize with one of the aforementioned polynucleotides under stringent conditions.
  • the oliguncleotides may consist of DNA or RNA or both.
  • Such oligonucleotides can be used as primers for PCR, as expression-inhibiting, antisense oligonucleotides, for RNA interference (RNAi) or for chimeric or genomic approaches.
  • RNAi RNA interference
  • RNAi methods are described, for example, in Fire et al., Nature (1998) 391: 806-811; Fire, Trends Genet. 15, 358-363 (1999); Sharp, RNA interference 2001. Genes Dev. 15, 485-490 (2001); Hammond et al. Nature Rev. Genet. 2, 11 10-11 19 (2001); Tuschl, Chem. Biochem. 2, 239-245 (2001); Hamilton et al., Science 286, 950-952 (1999); Hammond et al., Nature 404, 293-296 (2000); Zamore et al., Cell 101, 25-33 (2000); Bernstein et al., Nature 409, 363-366 (2001); Elbashir et al., Genes Dev.
  • the polynucleotides according to the invention can be used particularly effectively for the recombinant production of polyunsaturated fatty acids in host cells and transgenic organisms.
  • the proteins encoded by the polynucleotides of the invention encode polypeptides with ⁇ - 12 desaturase, ⁇ -4-desaturase, ⁇ -5 desaturase, ⁇ -5-elongase, ⁇ -6-desaturase and ⁇ -6-elongase activity can Ci 8 -, C 2 O and C 22 fatty acids with one, two, three, four or five double bonds, and preferably polyunsaturated Ci 8 fatty acids with one, two or three double bonds, such as C18: 1 ⁇ 9, C18: 2 ⁇ 9 '12 or C18: 3 ⁇ 9 ' 12 ' 15 , polyunsaturated C 2 o fatty acids having three or four double bonds such as C20: 3 ⁇ 8 ' 11 ' 14 or C20: 4
  • the fatty acids are desaturated in phospholipids or CoA fatty acid esters, advantageously in the CoA fatty acid esters.
  • a simple, inexpensive production of these polyunsaturated fatty acids is possible especially in eukaryotic systems.
  • the unsaturated fatty acids prepared by means of the polynucleotides of the invention can then be formulated as oil, lipid and fatty acid compositions and used accordingly.
  • the present invention further relates to a vector comprising the polynucleotide of the invention.
  • vector denotes a nucleic acid molecule which can transport another nucleic acid molecule, such as the polynucleotides according to the invention, to which it is bound.
  • vector is a circular double-stranded plasmid
  • DNA loop can be ligated into the additional DNA segments.
  • Another vector type is a viral vector, with additional DNA segments inserted into the viral vector
  • Genome can be ligated.
  • Certain vectors can autonomously replicate in a host cell into which they have been introduced (eg bacterial vectors with bacterial learn replication origin). Other vectors are advantageously integrated into the genome of a host cell upon introduction into the host cell and thereby replicated together with the host genome.
  • certain vectors may direct the expression of genes to which they are operably linked. These vectors are also referred to herein as expression vectors.
  • expression vectors suitable for recombinant DNA techniques are in the form of plasmids.
  • the terms plasmid and vector can be used interchangeably since the plasmid is the most commonly used vector form.
  • the invention is intended to encompass these other forms of expression vectors, such as viral vectors that perform similar functions.
  • vector is also intended to encompass other vectors known to those skilled in the art, such as phages, viruses such as SV40, CMV, TMV, transposons, IS elements, phasmids, phagemids, cosmids, linear or circular DNA, artificial chromosomes.
  • phages viruses such as SV40, CMV, TMV, transposons, IS elements, phasmids, phagemids, cosmids, linear or circular DNA, artificial chromosomes.
  • viruses such as SV40, CMV, TMV, transposons, IS elements, phasmids, phagemids, cosmids, linear or circular DNA, artificial chromosomes.
  • constructs for targeted, ie homologous recombination, or heterologous insertion of polynucleotides are examples of polynucleotides.
  • Vectors can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques.
  • transformation and “transfection”, conjugation and transduction are intended to encompass a variety of methods known in the art for introducing foreign nucleic acid (eg DNA) into a host cell, including calcium phosphate or calcium chloride coprecipitation, DEAE- Dextran-mediated transfection, lipofection, natural competence, chemically mediated transfer, electroporation or particle bombardment.
  • Suitable methods for transforming or transfecting host cells, including plant cells can be found in Sambrook et al.
  • Suitable cloning vectors are well known to those skilled in the art. These include, in particular, vectors which can be replicated in microbial systems, ie in particular vectors which ensure efficient cloning in yeasts or fungi, and which enable stable transformation of plants. Particular mention should be made of various binary and co-integrated vector systems suitable for T-DNA-mediated transformation. Such vector systems are usually characterized in that they contain at least the vir genes required for the Agrobacterium-mediated transformation as well as the T-DNA limiting sequences (T-DNA border). Preferably, these vector systems also comprise further cis-regulatory regions such as promoters and terminators and / or selection markers. ker, with which appropriately transformed organisms can be identified.
  • binary systems are based on at least two vectors, one of them vir genes, but no T-DNA and a second T-DNA, but no carries vir gene.
  • these binary vectors include vectors of the series pBI B-HYG, pPZP, pBecks, pGreen. Bin19, pB1101, pBinAR, pGPTV and pCAMBIA are preferably used according to the invention.
  • the vectors with the inserted polynucleotides according to the invention can be stably propagated in microorganisms, in particular Escherichia coli and Agrobacterium tumefaciens, under selective conditions and enable a transfer of heterologous DNA into plants or microorganisms.
  • the polynucleotides according to the invention can be introduced into organisms such as microorganisms or plants and thus be used for plant transformation. Suitable vectors for this are published in: Plant Molecular Biology and Biotechnology (CRC Press, Boca Raton, Florida), Chapter 6/7, pp.
  • the vector is an expression vector.
  • the polynucleotide is in operative (ie, functional) connection to an expression control sequence.
  • the expression control sequence together with the polynucleotide and optionally further sequence elements of the vector is also referred to as expression cassette.
  • the expression co-rolling sequence ensures that the polynucleotide can be expressed in a host cell after transformation or transfection.
  • the expression control sequence to be used preferably contains cis-regulatory elements such as promoter and / or enhancer nucleic acid sequences which are recognized by the transcription machinery of the host cells.
  • the term also includes other expression control elements such as polyadenylation signals and RNA stabilizing sequences.
  • the polynucleotides according to the invention may be present in one or more copies in the expression cassette or the expression vector according to the invention (for example in the form of several expression cassettes).
  • the regulatory sequences or factors can, as described above, preferably positively influence the gene expression of the introduced genes and thereby increase them.
  • enhancement of the regulatory elements can advantageously be done at the transcriptional level by using strong transcription signals such as promoters and / or enhancers.
  • an enhancement of the translation is possible by, for example, the stability of the mRNA is improved.
  • Further expression control sequences for the purposes of the present invention are translation terminators at the 3 'end of the polynucleotides to be translated.
  • the OCS1 terminator can be used here.
  • a different terminator sequence should be used here for each polynucleotide to be expressed.
  • Preferred expression control sequences or regulatory sequences are present in promoters, such as the cos, tac, trp, tet, trp-tet, lpp, lac, lpp-lac, laclq, T7, T5, T3 , gal, trc, ara, SP6, ⁇ -PR or ⁇ -PL promoter and are advantageously used in Gram-negative bacteria.
  • promoters amy and SPO2 in the yeast or fungal promoters ADC1, MFa, AC, P-60, CYC1, GAPDH, TEF, rp28, ADH or in the plant promoters CaMV / 35S [ Franck et al., Cell 21 (1980) 285-294], PRP1 [Ward et al., Plant. Biol. 22 (1993)], SSU, OCS, Iib4, usp, STLS1, B33, nos or in the ubiquitin or phaseolin promoter.
  • inducible promoters such as those in EP-AO 388 186 (benzylsulfonamide-inducible), Plant J.
  • EP-AO 335 528 Abzisinic inducible
  • WO 93/21334 ethanol or cyclohexenol inducible promoters.
  • Further suitable plant promoters are the promoter of cytosolic FBPase or the ST LSI promoter of the potato (Stockhaus et al., EMBO J. 8, 1989, 2445), the glycine max phosphoribosylprophosphate amidotransferase promoter (Genbank Accession No. U87999) or the nodia-specific promoter described in EP-A-0 249 676.
  • promoters which allow expression in tissues involved in fatty acid biosynthesis.
  • seed-specific promoters such as the USP Promoter but also other promoters such as the LeB4, DC3, phaseolin or napin promoter.
  • Further particularly advantageous promoters are seed-specific promoters which can be used for monocotyledonous or dicotyledonous plants and in US Pat. No. 5,608,152 (napin promoter from rapeseed), WO 98/45461 (oleosin promoter from Arobidopsis), US Pat. No.
  • the polynucleotides of the present invention should preferably be seed-specifically expressed in oilseeds.
  • seed-specific promoters can be used, or such promoters that are active in the embryo and / or in the endosperm.
  • seed-specific promoters can be isolated from both dicotolydone and monocotolydone plants.
  • acyl Carrier protein [US 5,315,001 and WO 92/18634], oleosin (Arabidopsis thaliana) [WO 98/45461 and WO 93/20216], phaseolin (Phaseolus vulgaris) [US 5,504,200], Bce4 [WO 91/13980] , Legumes B4 (LegB4 promoter) [Bäumlein et al., Plant J., 2,2, 1992], Lpt2 and lpt1 (barley) [WO 95/15389 u. WO95 / 23230], seed-specific promoters from rice, maize and the like.
  • Plant gene expression can also be facilitated by a chemically inducible promoter (see review in Gatz 1997, Annu Rev. Plant Physiol Plant Mol. Biol., 48: 89-108).
  • Chemically inducible promoters are particularly useful when it is desired that gene expression be in a time-specific manner. Examples of such promoters are a salicylic acid-inducible promoter (WO 95/19443), a tetracycline-inducible promoter (Gatz et al. (1992) Plant J. 2, 397-404) and an ethanol-inducible promoter.
  • each of the polynucleotides of the invention should be expressed under the control of their own preferred, a different promoter, since repeating sequence motifs can lead to instability of the T-DNA or to recombination events.
  • the expression cassette is advantageously constructed in such a way that a promoter is followed by a suitable interface for insertion of the nucleic acid to be expressed, advantageously followed by a terminator behind the polylinker in a polylinker.
  • This sequence is repeated several times, preferably three, four or five times, so that up to five genes can be brought together in one construct and thus introduced into the transgenic plant for expression.
  • the sequence is repeated up to three times.
  • each nucleic acid sequence has its own promoter and optionally its own terminator.
  • Such advantageous constructs are disclosed for example in DE 10102337 or DE 10102338.
  • the insertion site or the sequence of the inserted nucleic acids in the expression cassette is not of decisive importance, that is to say a nucleic acid sequence can be inserted at the first or last position in the cassette, without this significantly influencing the expression.
  • the recombinant expression vectors used may be designed for expression in prokaryotic or eukaryotic cells. This is advantageous since intermediate steps of the vector construction are often carried out in microorganisms for the sake of simplicity.
  • the ⁇ 12-desaturase, ⁇ 6-desaturase, ⁇ 6-elongase, ⁇ 5-desaturase, ⁇ 5-elongase and / or ⁇ -4-desaturase genes can be expressed in bacterial cells , Insect cells (using baculovirus expression vectors), yeast and other fungal cells (see Romanos, MA, et al., 1992 "Foreign gene expression in yeast: a review", Yeast 8: 423-488, van den Hondel, CAMJJ, et al.
  • Suitable host cells are further discussed in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990).
  • the recombinant expression vector may alternatively be transcribed and translated in vitro using, for example, T7 promoter regulatory sequences and T7 polymerase.
  • fusion expression vectors include pGEX (Pharmacia Biotech Ine, Smith, DB, and Johnson, KS (1988) Gene 67: 31-40), pMAL (New England Biolabs, Beverly, MA), and pRIT5 (Pharmacia, Piscataway, NJ). in which glutathione S-transferase (GST), maltose E-binding protein or protein A is fused to the recombinant target protein.
  • GST glutathione S-transferase
  • suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al.
  • Target gene expression from the pTrc vector is based on transcription by host RNA polymerase from a hybrid trp-lac fusion promoter.
  • Target gene expression from the pET 11 d vector is based on transcription from a T7 gn10-lac fusion promoter mediated by a co-expressed viral RNA polymerase (T7 gn1).
  • This viral polymerase is provided by the host strains BL21 (DE3) or HMS174 (DE3) from a resident ⁇ prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.
  • Other suitable vectors in prokaryotic organisms are known to those skilled in the art, these vectors are for example in E.
  • the pBR series such as pBR322
  • the pUC Series such as pUC18 or pUC19
  • the M1 13mp series pKC30, pRep4, pHS1, pHS2, pPLc236, pMBL24
  • pLG200
  • the expression vector is a yeast expression vector.
  • yeast expression vectors for expression in the yeast S. cerevisiae include pYeDesaturased (Baldari et al. (1987) Embo J. 6: 229-234), pMFa (Kurjan and Herskowitz (1982) Cell 30: 933-943), pJRY88 (Schultz et al. (1987) Gene 54: 113-123) and pYES2 (Invitrogen Corporation, San Diego, CA).
  • Vectors and methods for constructing vectors suitable for use in other fungi, such as filamentous fungi include those described in detail in: van den Hondel, C.A.M.J.J., & Punt, PJ.
  • yeast vectors are, for example, pAG-1, YEp6, YEp13 or pEMBLYe23.
  • polynucleotides of the present invention may also be expressed in insect cells using baculovirus expression vectors.
  • Baculovirus vectors that are available for expression of proteins in cultured insect cells include the pAc series (Smith et al., (1983) Mol. Cell Biol. 3: 2156-2165) and U.S. Pat pVL series (Lucklow and Summers (1989) Virology 170: 31-39).
  • Preferred plant expression vectors include those described in detail in: Becker, D., Kemper, E., Schell, J., and Masterson, R. (1992) "New plant binary vectors with selectable markers located proximal to the left border Biol. 20: 1 195-1 197; and Bevan, MW (1984) "Binary Agrobacterium vectors for plant transformation", Nucl. Acids Res. 12: 871 1-8721; Vectors for Gene Transfer to Higher Plants; in: Transgenic Plants, Vol. 1, Engineering and Utilization, eds .: Kung and R. Wu, Academic Press, 1993, pp. 15-38.
  • a plant expression cassette preferably contains expression control sequences which can direct gene expression in plant cells and are operably linked so that each sequence can fulfill its function, such as termination of transcription, for example polyadenylation signals.
  • Preferred polyadenylation signals are those derived from Agrobacterium tumefaciens T-DNA, such as the gene 3 of the Ti plasmid pTiACH ⁇ known as octopine synthase (Gielen et al., EMBO J. 3 (1984) 835ff.) Or functional equivalents thereof, as well all other terminators functionally active in plants are suitable.
  • a plant expression cassette preferably contains other operably linked sequences such as translation enhancers such as the overdrive sequence containing the tobacco mosaic virus 5 'untranslated leader sequence which increases the protein / RNA ratio (Gallie et al , 1987, Nucl. Acids Research 15: 8693-871 1).
  • Plant gene expression, as described above, must be operably linked to a suitable promoter that performs gene expression in a timely, cell or tissue-specific manner.
  • Useful promoters are constitutive promoters (Benfey et al., EMBO J.
  • telomeres are preferred sequences necessary to direct the gene product into its corresponding cell compartment (see review in Kermode, Crit., Plant, 15, 4 (1996) 285) -423 and references cited therein), for example to the vacuole, the nucleus, all types of plastids, such as amyloplasts, chloroplasts, chromoplasts, the extracellular space, the mitochondria, the endoplasmic reticulum, oil bodies, peroxisomes, and other compartments of plant cells.
  • plastids such as amyloplasts, chloroplasts, chromoplasts, the extracellular space, the mitochondria, the endoplasmic reticulum, oil bodies, peroxisomes, and other compartments of plant cells.
  • Plant gene expression can also be facilitated by a chemically inducible promoter as described above (see review in Gatz 1997, Annu Rev. Plant Physiol Plant Mol. Biol., 48: 89-108).
  • Chemically inducible promoters are particularly useful when it is desired that gene expression be in a time-specific manner. Examples of such promoters are a salicylic acid-inducible promoter (WO 95/19443), a tetracycline-inducible promoter (Gatz et al. (1992) Plant J. 2, 397-404) and an ethanol-inducible promoter.
  • Promoters which react to biotic or abiotic stress conditions are also suitable promoters, for example the pathogen-induced PRP1 gene promoter (Ward et al., Plant Mol. Biol. 22 (1993) 361-366), the heat-inducible hsp ⁇ O promoter Tomato (US 5,187,267), the potato inducible alpha-amylase promoter (WO 96/12814) or the wound inducible pinI I promoter (EP-A-0 375 091).
  • the pathogen-induced PRP1 gene promoter Ward et al., Plant Mol. Biol. 22 (1993) 361-366
  • the heat-inducible hsp ⁇ O promoter Tomato US 5,187,267
  • the potato inducible alpha-amylase promoter WO 96/1281
  • the wound inducible pinI I promoter EP-A-0 375 091
  • promoters which induce gene expression in tissues and organs in which the fatty acid, lipid and oil biosynthesis takes place in sperm cells such as the cells of the endosperm and the developing embryo.
  • Suitable promoters are the rapeseed napkin promoter (US 5,608,152), the Vicia faba USP promoter (Baeumlein et al., Mol Gen Genet, 1991, 225 (3): 459-67), the Arabidopsis oleosin promoter (US Pat. WO 98/45461), the phaseolin promoter from Phaseolus vulgaris (US Pat. No.
  • Bce4 promoter Brassica WO 91/13980
  • legumin B4 promoter (LeB4; Baeumlein et al., 1992, Plant Journal, 2 (2): 233-9)
  • promoters expressing seed-specific expression in monocotyledonous plants such as maize To bring in barley, wheat, rye, rice, etc.
  • Suitable noteworthy promoters are the lpt2 or lpt1 gene promoter from barley (WO 95/15389 and WO 95/23230) or those described in WO 99/16890 (promoters from the barley hordein gene, the rice glutelin gene , the rice oryzin gene, the rice prolamin gene, the wheat gliadin gene, the wheat glutelin gene, the maize zein gene, the oat glutelin gene, the sorghum kasirin gene, the rye secalin gene).
  • promoters which induce plastid-specific expression since plastids are the compart- ment in which the precursors as well as some end products of lipid biosynthesis are synthesized.
  • Suitable promoters such as the viral RNA polymerase promoter, are described in WO 95/16783 and WO 97/06250, and the cIpP promoter from Arabidopsis described in WO 99/46394.
  • the expression vector may, as described above, also include other genes to be introduced into the organisms. It is possible and preferred to introduce into the host organisms regulatory genes, such as genes for inducers, repressors or enzymes, which intervene by their enzyme activity in the regulation of one or more genes of a biosynthetic pathway, and to express therein. These genes may be of heterologous or homologous origin. Heterologous genes or polynucleotides are derived from a parent organism that differs from the target organism into which the genes or polynucleotides are to be introduced. For homologous genes or polynucleotides, the target organism and the parent organism are the same.
  • the vector comprises at least one further polynucleotide encoding a further enzyme involved in the biosynthesis of lipids or fatty acids.
  • CoA lysophospholipid acyltransferase (s), fatty acid synthase (s), fatty acid hydroxylase (s), acetyl coenzyme A carboxylase (s), acyl coenzyme A oxidase (s), Fatty acid desaturase (s), fatty acid acetylenase (s), lipoxygenase (s), triacylglycerol lipase (s), allene oxide synthase (s), hydroperoxide lyase (s), fatty acid elongase (s), ⁇ 4-desaturase (n), ⁇ 5-desaturase (s), ⁇ 6-desaturase (s), ⁇ 8-desaturase (s), ⁇ 9-desaturase (s), ⁇ 12-desaturase (s), ⁇ 5-elongase (s), ⁇ 6-elongase ( n) and ⁇ 9 elongase (
  • the invention also relates to a host cell comprising the polynucleotide or vector of the invention.
  • Host cells may in principle be any eukaryotic or prokaryotic cells. They may be primary cells from animals, plants or multicellular microorganisms, e.g. from those mentioned elsewhere in the description. Furthermore, the term also includes cell lines that can be obtained from these organisms.
  • host cells according to the invention may also be unicellular microorganisms, for example bacteria or fungi.
  • Particularly preferred microorganisms are fungi selected from the family of Chaetomiaceae, Choanephoraceae, Cryptococceae, Cunninghamellaceae, Demetiaceae, Moniliaceae, Mortierellaceae, Mucoraceae, Pythiaceae, Sacharomycetaceae, Saprolegniaceae, Schizosacharomycetaceae, Sodariaceae or Tuberculariaceae.
  • Choanephoraceae such as the genera Blakeslea, Choanephora eg the genera and species Blakeslea trispora, Choanephora cucurbiturum, Choanephora infundibulifera var.
  • Mortierellaceae such as the genus Mortierella eg the genera and species Mortierella isabellina, Mortierella polycephala , Mortierella ramanniana, Mortierella vinacea, Mortierella zonata, Pythiaceae such as the genera Phytium, Phytophthora eg the genera and species Pythium debaryanum, Pythium intermedium, Irregular Pythium, Pythium megalacanthum, Pythium paro-candrum, Pythium sylvaticum, Pythium ultimum, Phytophthora cactorum, Phytophthora cinnamomi , Phytophthora citricola, Phytophthora citrophthora, Phytophthora cryptogea, Phytophthora drechsleri, Phytophthora erythroseptica, Phytophthora lateralis, Phytophthora mega
  • Minuta Pichia minuta var nonfermentans, Pichia norvegensis, Pichia ohmeri, Pichia pastoris, Pichia philodendri, Pichia pini, Pichia polymorpha, Pichia quercuum , Pichia rhodanensis, Pichia sargentensis, Pichia stipitis, Pichia strasburgensis, Pichia subpelliculosa, Pichia toletana, Pichia trehalophila, Pichia vini, Pichia xylosa, Saccharomyces aceti, Saccharomyces bailii, Saccharomyces bayanus, Saccharomyces bisporus, Saccharomyces capensis, Saccharomyces carlsbergensis, Saccharomyces cerevisiae , Saccharomyces cerevisiae var.
  • pombe Thraustochytriaceae as the genera Althornia, Aplanochytrium, Japonochytrium, Schizochytrium, Thraustochytrium eg the species Schizochytrium aggregatum, Schizochytrium limacinum, Schizochytrium mangrovei, Schizochytrium minutum, Schizochytrium octosporum, Thraustochytrium aggregatum, Thraustochytrium amoeboideum, Thraustochytrium antacticum, arudimentale Thraustochytrium, Thraustochytrium aureum, benthicola Thraustochytrium, Thraustochytrium globosum, Thraustochytrium indicum, Thraustochytrium kerguelense, Thraustochytrium kinnei, Thraustochytrium motivum, Thraustochytrium multi Rudi mental, Thraustochytrium pachyder-
  • bacteria selected from the group of the families Bacillaceae, Enterobacteriacae or Rhizobiaceae are particularly preferred. Particularly preferred are the following bacteria selected from the group: Bacillaceae such as the genus Bacillus eg the genera and species Bacillus acidocaldarius, Bacillus acidoterrestris, Bacillus alcalophilus, Bacillus amyloliquefaciens, Bacillus amylolyticus, Bacillus brevis, Bacillus cereus, Bacillus circulans, Bacillus coagulans, Bacillus sphaericus subsp.
  • Bacillaceae such as the genus Bacillus eg the genera and species Bacillus acidocaldarius, Bacillus acidoterrestris, Bacillus alcalophilus, Bacillus amyloliquefaciens, Bacillus amylolyticus, Bacillus brevis, Bacillus cereus, Bacillus circulans, Bacillus coagul
  • Enterobacteriacae such as the genera Citrobacter, Edwardsieila, Enterobacter, Erwinia, Escherichia, Klebsiella, Salmonella or Serratia eg the genera and species Citrobacter amalonaticus, Citrobacter diversus, Citrobacter freundii, Citrobacter genomospecies, Citrobacter gillenii, Citrobacter intermedium, Citrobacter koseri, Citrobacter murliniae, Citrobacter sp , Edwardsiella hoshinae, Edwardsiella ictaluri, Edwardsiella tarda, Erwinia alni, Erwinia amylovora, Erwiniaananatis, Erwinia aphidicola, Erwinia billingiae, Erwinia cacticida, Erwinia carcinogena, Erwinia carnegieana, Erwinia caro
  • Escherichia coli mutabile Escherichia fergusonii
  • Escherichia hermannii Escherichia sp.
  • Escherichia vulneris Escherichiella aerogenes
  • Klebsiella edwardsii subsp. atlantae Klebsiella ornithinolytica
  • Klebsiella oxytoca Klebsiella planticola
  • Klebsiella pneumoniae Klebsiella pneumoniae subsp.
  • Salmonella daressalaam Salmonella enterica subsp. houtenae, Salmonella enterica subsp. salamae, Salmonella enteritidis, Salmonella gallinarum, Salmonella heidelberg, Salmonella panama, Salmonella senftenberg, Salmonella typhimurium, Serratia entomophila, Serratia ficaria, Serratia fonticola, Serratia grimesii, Serratia liquefaciens, Serratia marcescens, Serratia marcescens subsp.
  • Rhizobiaceae such as the genera Agrobacterium, Carbophilus, Chelatobacter, Ensifer, Rhizobium, Sinorhizobium eg the genera and species Agrobacterium atlanticum, Agrobacterium ferrugineum, Agrobacterium gelatinovorum, Agrobacterium larrymoorei, Agrobacterium meteori, Agrobacterium radiobacter, Agrobacterium rhizogenes, Agrobacterium rubi, Agrobacterium stellulatum, Agrobacterium tumefaciens, Agrobacterium vitis, Carbophilus carboxidus, Chelatobacter heintzii
  • Useful host cells are also mentioned in: Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990).
  • Useful expression strains e.g. those which have lower protease activity are described in: Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 119-128.
  • These include plant cells and certain tissues, organs and parts of plants in all their forms such as anthers, fibers, root hairs, stems, embryos, cilia, kotelydones, petioles, crops, plant tissue, reproductive tissue and cell cultures transgenic plant is derived and / or can be used to produce the transgenic plant.
  • Polynucleotides or vectors may be introduced into the host cell using transformation or transfection techniques known in the art, as previously described. Conditions and media for the cultivation of the host cells are also known to the person skilled in the art.
  • the host cell according to the invention preferably additionally comprises at least one further enzyme, which is involved in the biosynthesis of lipids or fatty acids.
  • Enzyme can be present endogenously in the host cell, ie the host cell already naturally expresses a gene which codes for a corresponding enzyme.
  • a heterologous polynucleotide may be introduced into the host cell encoding the enzyme. Suitable methods and measures for the expression of a Heterologous polynucleotides are known in the art and described herein in connection with the polynucleotides, vectors and host cells of the present invention.
  • the invention also relates to a method for producing a polypeptide having desaturase or elongase activity comprising the steps:
  • the polypeptide can be obtained by all common methods for protein purification.
  • the methods include, for example, affinity chromatography, molecular sieve chromatography, high-pressure liquid chromatography or protein precipitation optionally with specific antibodies.
  • the method need not necessarily provide a pure preparation of the polypeptide.
  • the invention thus also relates to a polypeptide which is encoded by the polynucleotide according to the invention or which is obtainable by the abovementioned method according to the invention.
  • polypeptide refers to both a substantially pure polypeptide and a polypeptide preparation that contains other components or contaminants.
  • the term is also used for fusion proteins or protein aggregates comprising the polypeptide of the invention and additionally further components.
  • the term also refers to chemically modified polypeptides. Chemical modifications in this context include artificial modifications or naturally occurring modifications, eg, post-translational modifications such as phosphorylation, myristylation, glycosylation, etc.
  • polypeptide, peptide, or protein are interchangeable and are used accordingly in the description and in the prior art.
  • polypeptides according to the invention have the abovementioned biological activities, ie desaturase or elongase activities, and can influence the biosynthesis of polyunsaturated fatty acids (PUFAs), preferably the long-chain PUFAs (LCPUFAs), as described herein.
  • PUFAs polyunsaturated fatty acids
  • LCPUFAs long-chain PUFAs
  • the invention also encompasses an antibody which specifically recognizes the polypeptide according to the invention.
  • Antibodies to the polypeptide of the invention may be prepared by known methods using purified polypeptide or fragments thereof with appropriate epitopes as the antigen. Suitable epitopes can be determined by known antigenicity determination algorithms based on the amino acid sequences of the polypeptides of the invention provided herein. The corresponding polypeptides or fragments can then be synthesized or recombinantly recovered. After immunization of animals, preferably mammals e.g. Rabbits, rats or mice, the antibodies can then be recovered from the serum by known methods. Alternatively, monoclonal antibodies or antibody fragments may be provided by known methods; see, e.g. Harlow and Lane “Antibodies, A Laboratory Manual", CSH Press, Colard Spring Harbor, 1988, or Kohler and Milstein, Nature 256 (1975), 495, and Galfre, Meth. Enzymol. 73 (1981), 3.
  • the antibodies are preferably monoclonal or polyclonal antibodies, single-chain antibodies or chimeric antibodies and fragments thereof such as Fab, Fv or scFv. Further antibodies within the meaning of the invention are bispecific antibodies, synthetic antibodies or their chemically modified derivatives.
  • the antibodies of the invention are intended to specifically recognize the polypeptides of the invention, i. they should not crossreact with other proteins to any significant extent. This can be tested by methods known in the art.
  • the antibodies can be used, for example, for immunoprecipitation, for immunohistochemistry or for protein purification (for example affinity chromatography).
  • the invention further relates to a transgenic non-human organism comprising the polynucleotide, the vector or the host cell of the present invention.
  • the transgenic, non-human organism is an animal, a plant or a multicellular microorganism.
  • transgenic is to be understood as meaning that a heterologous polynucleotide, ie a polynucleotide which does not naturally occur in the particular organism, is introduced into the organism, which can be achieved either by random insertion of the polynucleotide or by homologous recombination it is also possible to introduce the vector according to the invention instead of the polynucleotide become.
  • Methods for introducing polynucleotides or vectors for random insertion or homologous recombination are known in the art and also described in more detail below.
  • Host cells containing the polynucleotide or vector may also be introduced into an organism to produce a transgenic organism. However, such an organism is then a chimeric organism in which only the cells which are derived from the introduced cells are transgenic, ie comprise the heterologous polynucleotide.
  • transgenic non-human organisms oil-producing organisms that is, used for the production of oils, such as fungi such as Mortierella or Thraustochytrium, algae such as Nephroselmis, Pseudoscourfielda, Prasinococcus, Scherffelia, Tetraselmis, Mantoniella, Ostreococcus, Crypthecodinium, Phaeodactylum or plants.
  • oils such as fungi such as Mortierella or Thraustochytrium, algae such as Nephroselmis, Pseudoscourfielda, Prasinococcus, Scherffelia, Tetraselmis, Mantoniella, Ostreococcus, Crypthecodinium, Phaeodactylum or plants.
  • all plants can be used as transgenic plants, ie both dicotyledonous and monocotyledonous plants.
  • they are oilseed crops containing high levels of lipid compounds such as peanut, rapeseed, canola, sunflower, safflower (Carthamus tinctoria), poppy, mustard, hemp, castor, olive, sesame, calendula, punica, evening primrose, mullein, thistle , Wild roses, hazelnut, almond, macadamia, avocado, bay leaf, pumpkin, flax, soy, pistachio, borage, trees (oil palm, coconut or walnut) or crops such as corn, wheat, rye, oats, triticale, rice, barley, cotton , Cassava, pepper, tagetes, solanaceae plants such as potato, tobacco, aubergine and tomato, Vicia species, pea, alfalfa or bush plants (coffee, cocoa, tea), Salix species and perennial grass
  • Preferred plants according to the invention are oil crop plants, such as peanut, rapeseed, canola, sunflower, safflower, poppy, mustard, hemp, castor, olive, calendula, punica, evening primrose, pumpkin, flax, soy, borage, trees (oil palm, coconut).
  • Particularly preferred are C18: 2 and / or C18: 3 fatty acid rich plants such as sunflower, safflower, tobacco, mullein, sesame, cotton, pumpkin, poppy, evening primrose, walnut, flax, hemp, thistle or safflower.
  • plants such as safflower, sunflower, poppy, evening primrose, walnut, flax or hemp.
  • plants which are able to synthesize fatty acids as all dicotyledonous or monocotyledonous plants, algae or mosses.
  • Advantageous plants are selected from the group of the plant families Adelotheciaceae, Anacardiaceae, Asteraceae, Apiaceae, Betulaceae, Boraginaceae, Brassicaceae, Bromeliaceae, Caricaceae, Cannabaceae, Convolvulceae, Chenopodiaceae, Crypthecodiniaceae, Cucurbitaceae, Ditrichaceae, Elaeagaceae, Ericaceae, Euphorbiaceae, Fabaceae , Geraniaceae, Gramineae, Juglandaceae, Lauraceae, Leguminosae, Linaceae, Prasinophyceae or vegetables or ornamental plants such as Tagetes.
  • Adelotheciaceae such as the genera Physcomitrella eg the genus and species Physcomitrella patens
  • Anacardiaceae such as the genera Pistacia, Mangifera, Anacardium eg the genus and species Pistacia vera [pistachio], Mangifer indica [ Mango] or Anacardium occidentale [Cashew]
  • Asteraceae such as the genera Calendula, Carthus, Centaurea, Cichorium, Cynara, Helianthus, Lactuca, Locusta, Tagetes, Valeriana eg the genus and species Calendula officinalis [Gardening Marigold], Carthamus tinctorius [ Safflower], Centaurea cyanus [cornflower], Cichorium intybus [chicory], Cynara scolymus [Artichoke], Helianthus annus [sunflower], Lactuca sativa, Lact
  • [Cayenne pepper] such as the genera Hordeum, Seeale, Avena, Sorghum, Andropogon, Holcus, Panicum, Oryza, Zea (maize), Triticum eg the genera and species Hordeum vulgare, Hordeum jubatum, Hordeum murinum, Hordeum secalinum, Hordeum distichon Hordeum aegiceras, Hordeum hexastichonum, Hordeum hexastichum, Hordeum irregular, Hordeum sativum, Hordeum secalinum [barley], Seeale cereale [rye], Avena sativa, Avena fatua, Avena byzantina, Avena fatua var.
  • Multicellular microorganisms that can be used as transgenic non-human organisms are preferably protists or diatoms selected from the group of the family Dinophyceae, Turaniellidae or Oxytrichidae such as the genera and species: Crypthecodinium cohnii, Phaeodactylum tricornutum, Stylonychia mytilus, Stylonychia pustulata, Stylonychia putrina , Stylonychia notophora, Stylonychia sp., Colpidium campylum or Colpidium sp.
  • protists or diatoms selected from the group of the family Dinophyceae, Turaniellidae or Oxytrichidae such as the genera and species: Crypthecodinium cohnii, Phaeodactylum tricornutum, Stylonychia mytilus, Stylonychia pustulata, Stylonychia putrina
  • the invention relates to a process for producing a substance having the structure shown in the following general formula I.
  • R 1 hydroxyl, coenzyme A (thioester), lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysodiphosphatidylglycerol,
  • Lysophosphatidylserine lysophosphatidylinositol, sphingolase or a radical of formula II
  • R 2 hydrogen, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysodiphosphatidylglycerol, lysophosphatidylserine, lysophosphatidylinositol or saturated or unsaturated C 2 -C 24 -alkylcarbonyl,
  • R 3 hydrogen, saturated or unsaturated C 2 -C 24 -alkylcarbonyl, or R 2 and R 3 are independently of one another a radical of the formula Ia:
  • the method comprises culturing (i) a host cell of the invention or (ii) a transgenic non-human of the invention under conditions permitting biosynthesis of the substance.
  • the aforementioned substance is provided in an amount of at least 1% by weight based on the total content of the lipids in the host cell or the transgenic organism.
  • R 1 in general formula I denotes hydroxyl, coenzyme A (thioester), lysophosphatidylcholine, lyso-phosphatidylethanolamine, lyso-phosphatidylglycerol, lyso-diphosphatidylglycerol, lyso-phosphatidylserine, lyso-phosphatidylinositol, sphingobase, or a radical of the general formula II
  • R 1 are always bonded in the form of their thioesters to the compounds of general formula I.
  • R 2 in the general formula II denotes hydrogen, lyso-phosphatidylcholine, lyso-phosphatidylethanolamine, lyso-phosphatidylglycerol, lyso-diphosphatidylglycerol, lyso-phosphatidylserine, lyso-phosphatidylinositol or saturated or unsaturated C 2 -C 24 - alkylcarbonyl.
  • Suitable alkyl radicals are substituted or unsubstituted, saturated or unsaturated C 2 -C 24 -alkylcarbonyl chains such as ethylcarbonyl, n-propylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl, n-hexylcarbonyl, n-heptylcarbonyl, n- Octylcarbonyl, n-nonylcarbonyl, n-decylcarbonyl, n-undecylcarbonyl, n-dodecylcarbonyl, n-tridecylcarbonyl, n-tetradecylcarbonyl, n-pentadecylcarbonyl, n-hexadecylcarbonyl, n-heptadecylcarbonyl, n- Octadecylcarbonyl, n-nonadecylcarbonyl,
  • C 1 -C 22 -alkylcarbonyl radicals such as n-decylcarbonyl, n- Undecylcarbonyl, n-dodecylcarbonyl, n-tridecylcarbonyl, n-tetradecylcarbonyl, n-pentadecylcarbonyl, n-hexadecylcarbonyl, n-heptadecylcarbonyl, n-octadecylcarbonyl, n-nonadecylcarbonyl, n-eicosylcarbonyl, n- Docosanylcarbonyl or n-tetracosanylcarbonyl- containing one or more double bonds are preferred.
  • saturated and / or unsaturated C 0 -C 22 - radicals such as Cio-alkylcarbonyl, Cn-alkylcarbonyl, Ci2-alkylcarbonyl, Ci 3 - alkylcarbonyl, Ci 4 -alkylcarbonyl, C 6 alkylcarbonyl, Ci ⁇ -alkylcarbonyl, C 20 - alkylcarbonyl or C 22 -alkylcarbonyl radicals which contain one or more double bonds.
  • C 1 -C 22 -alkylcarbonyl radicals such as C 1 -C 6 -alkylcarbonyl, C 1-6 -alkylcarbonyl, C 20 -alkylcarbonyl or C 22 -alkylcarbonyl radicals which contain one or more double bonds.
  • These advantageous radicals may contain two, three, four, five or six double bonds.
  • the particularly advantageous radicals having 20 or 22 carbon atoms in the fatty acid chain contain up to six double bonds, advantageously three, four, five or six double bonds, more preferably five or six double bonds. All these radicals are derived from the corresponding fatty acids.
  • R 3 in the general formula II is hydrogen, saturated or unsaturated C 2 -C 24 -alkylcarbonyl.
  • Suitable alkyl radicals are substituted or unsubstituted, saturated or unsaturated C 2 -C 24 -alkylcarbonyl chains such as ethylcarbonyl, n-propylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl, n-hexylcarbonyl, n-heptylcarbonyl, n- Octylcarbonyl, n-nonylcarbonyl, n-decylcarbonyl, n-undecylcarbonyl, n-dodecylcarbonyl, n-tridecylcarbonyl, n-tetradecylcarbonyl, n-pentadecylcarbonyl, n-pentadecylcarbonyl, n-
  • C 1 -C 22 -alkylcarbonyl radicals such as n-decylcarbonyl, n-undecylcarbonyl, n-dodecylcarbonyl, n-tridecylcarbonyl, n-tetradecylcarbonyl, n-pentadecylcarbonyl, n-hexadecylcarbonyl, n-heptadecylcarbonyl , n-octadecylcarbonyl, n-nonadecylcarbonyl, n-eicosylcarbonyl, n-docosanylcarbonyl or n-tetracosanylcarbonyl containing one or more double bonds are preferred.
  • C 1 -C 22 -alkylcarbonyl radicals such as C 1 -C 6 -alkylcarbonyl, C 1-6 -alkylcarbonyl, C 20 -alkylcarbonyl or C 22 -alkylcarbonyl radicals which contain one or more double bonds.
  • These Advantageous radicals may contain two, three, four, five or six double bonds.
  • the particularly advantageous radicals having 20 or 22 carbon atoms in the fatty acid chain contain up to six double bonds, advantageously three, four, five or six double bonds, more preferably five or six double bonds. All these radicals are derived from the corresponding fatty acids.
  • R 1 , R 2 and R 3 may be substituted by hydroxyl and / or epoxy groups and / or may contain triple bonds.
  • the polyunsaturated fatty acids prepared in the process according to the invention contain at least two, advantageously three, four, five or six double bonds. Particularly advantageously, the fatty acids contain four five or six double bonds.
  • Fatty acids produced in the process advantageously have 18, 20 or 22 carbon atoms in the fatty acid chain, preferably the fatty acids contain 20 or 22 carbon atoms in the fatty acid chain.
  • saturated fatty acids are little or not reacted with the nucleic acids used in the process. Little is understood to mean that compared to polyunsaturated fatty acids, the saturated fatty acids have less than 5% of the activity, advantageously less than 3%, more preferably less than 2%, most preferably less than 1; 0.5; 0.25 or 0.125% are implemented. These produced fatty acids can be produced as the only product in the process or present in a fatty acid mixture.
  • the substituents R 2 or R 3 in the general formulas I and II independently of one another denote saturated or unsaturated C 8 -C 22 -alkylcarbonyl, particularly advantageously independently they denote unsaturated C 8 -, C 2 o- or C 22 -alkylcarbonyl - with at least two double bonds.
  • the polyunsaturated fatty acids produced in the process are advantageously bound in membrane lipids and / or triacylglycerides, but may also be present as free fatty acids or bound in the form of other fatty acid esters in the organisms. They may be present as "pure products" or advantageously in the form of mixtures of different fatty acids or mixtures of different glycerides.
  • the different fatty acids bound in the triacylglycerides can thereby be derived from short-chain fatty acids having 4 to 6 C atoms, medium-chain fatty acids having 8 to 12 C atoms or long-chain fatty acids having 14 to 24 C atoms, preferably the long-chain fatty acids are particularly preferred the long-chain fatty acids LCPUFAs of Ci 8 , C 2 o and / or C 22 fatty acids.
  • the fatty acid ester with polyunsaturated C 8 -, C 2 0 and / or C 22 -Fettklare- molecules can be isolated from the organisms which have been used for the production of the fatty acid ester, in the form of an oil or lipid, for example in the form of compounds such as sphingolipids, Phosphoglycerides, lipids, glycolipids such as glycosphingolipids, phospholipids such as phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol or diphosphatidylglycerol, monoacylglycerides, diacylglycerides, triacylglycerides or other fatty acid esters such as the acetyl-coenzymeA esters which contain at least two polyunsaturated fatty acids Preferably, they are isolated in the form of their diacylglycer
  • the polyunsaturated fatty acids are also included as free fatty acids or bound in other compounds in the organisms beneficial to the plants.
  • the various abovementioned compounds (fatty acid esters and free fatty acids) in the organisms have an approximate distribution of 80 to 90% by weight of triglycerides, 2 to 5% by weight of diglycerides, 5 to 10% by weight of monoglycerides , 1 to 5 wt .-% of free fatty acids, 2 to 8 wt .-% phospholipids ago, wherein the sum of the various compounds to 100 wt .-% complements.
  • the LCPUFAs produced are present in a content of at least 3% by weight, advantageously of at least 5% by weight, preferably of at least 8% by weight, more preferably of at least 10% by weight, very particularly preferably at least 15 wt .-% based on the total fatty acids in the transgenic organisms advantageously produced in a transgenic plant.
  • advantageously Ci 8 - and / or C 2 o fatty acids in the host organisms are present, at least 10%, advantageously at least 20%, more preferably at least 30%, most preferably at least 40% in the corresponding products such as DPA or DHA, to name only two exemplified implemented.
  • the fatty acids are prepared in bound form.
  • these unsaturated fatty acids can be brought to the sn1, sn2 and / or sn3 position of the advantageously prepared triglycerides.
  • the starting compounds linoleic acid (C18: 2) or linolenic acid (C18: 3) undergo several reaction steps in the process according to the invention, the end products of the process, such as, for example, arachidonic acid (ARA), eicosapentaenoic acid (EPA), ⁇ -6-docosapentaenoic acid or DHA, are precipitated not as absolute pure products, there are always also small traces of precursors in the final product included.
  • ARA arachidonic acid
  • EPA eicosapentaenoic acid
  • DHA ⁇ -6-docosapentaenoic acid
  • the end products such as ARA, EPA or DHA are present as mixtures.
  • the precursors should advantageously not more than 20 wt .-%, preferably not more than 15 wt .-%, more preferably not more than 10 wt .-%, most preferably not more than 5 wt .-% based on the amount of the respective Final product amount.
  • ARA, EPA or only DHA are bound in the process according to the invention or produced as free acids in a transgenic plant as end products.
  • the compounds ARA, EPA and DHA are prepared simultaneously, they are advantageously used in a ratio of at least 1: 1: 2 (EPA: ARA: DHA), preferably of at least 1: 1: 3, preferably of 1: 1: 4 preferably prepared from 1: 1: 5.
  • Fatty acid esters or fatty acid mixtures which have been prepared by the process according to the invention advantageously contain 6 to 15% palmitic acid, 1 to 6% stearic acid; 7 - 85% oleic acid; 0.5 to 8% of vaccenic acid, 0.1 to 1% of arachidic acid, 7 to 25% of saturated fatty acids, 8 to 85% of monounsaturated fatty acids and 60 to 85% of polyunsaturated fatty acids in each case based on 100% and on the total fatty acid content of the organisms.
  • polyunsaturated fatty acid in the fatty acid esters or fatty acid mixtures are preferably at least 0.1; 0.2; 0.3; 0.4; 0.5; 0.6; 0.7; 0.8; 0.9 or 1% based on the total fatty acid content of arachidonic acid.
  • the fatty acid esters or fatty acid mixtures prepared by the process according to the invention advantageously contain fatty acids selected from the group of the fatty acids erucic acid (13-docosaic acid), sterculic acid (9,10-methylene octadec-9-enoic acid), malvalic acid (8,9 -Methylene heptadec-8-enoic acid), chaulmoogric acid (cyclopentenodecanoic acid), furan fatty acid (9,12-epoxy-octadeca-9,1-dienanoic acid), vernonoic acid (9,10-epoxyoctadec-12-enoic acid) , Taric acid (6-octadecynoic acid), 6-nonadecynoic acid, santalbic acid (t11-octadecen-9-ynoic acid), 6,9-octadecenynoic acid, pyrulic acid (t10-h
  • fatty acids are generally advantageously present only in traces in the fatty acid esters or fatty acid mixtures prepared by the process according to the invention, that is to say they are less than 30%, preferably less than 25%, 24%, 23%, based on the total fatty acids. , 22% or 21%, more preferably less than 20%, 15%, 10%, 9%, 8%, 7%, 6% or 5%, most preferably less than 4%, 3%, 2% or 1% ago.
  • the nucleic acid sequences according to the invention or the nucleic acid sequences used in the method according to the invention can increase the yield of polyunsaturated fatty acids by at least 50%, advantageously by at least 80%, particularly advantageously by at least 100%, very particularly advantageously by at least 150% compared to the non-transgenic starting organism
  • a yeast, an alga, a fungus, or a plant such as Arabidopsis or flax can be obtained by comparison in GC analysis, see Examples.
  • chemically pure polyunsaturated fatty acids or fatty acid compositions can be prepared by the methods described above.
  • the fatty acids or fatty acid compositions from the organism such as the microorganisms or plants or the culture medium in which or on which the organisms were grown, or from the organism and the culture medium in a known manner, for example via extraction, distillation, crystallization, chromatography or Isolated combinations of these methods.
  • These chemically pure fatty acids or fatty acid compositions are advantageous for applications in the food industry, the cosmetics industry and especially the pharmaceutical industry.
  • acyl-CoA dehydrogenase s
  • acyl-CoA dehydrogenase s
  • genes selected from the group of ⁇ -4-desaturases, ⁇ -5-desaturases, ⁇ -6-desaturases, ⁇ -9-desaturases, ⁇ -12-desaturases, ⁇ -6-elongases or ⁇ - 5- elongases used in combination with the polynucleotides of the invention, wherein single genes or multiple genes can be used in combination.
  • the desaturases used in the process of the invention convert their respective substrates in the form of the CoA fatty acid esters.
  • the respective desaturation products are thereby synthesized in higher amounts, since the elongation step usually takes place on the CoA fatty acid esters, while the desaturation step takes place predominantly on the phospholipids or on the triglycerides.
  • An exchange reaction that would require another possibly limiting enzyme reaction between the CoA fatty acid esters and the phospholipids or triglycerides is thus not required.
  • the enzymatic activity of the polypeptides used in the process according to the invention makes it possible to prepare a wide variety of polyunsaturated fatty acids in the process according to the invention.
  • the various polyunsaturated fatty acids or individual polyunsaturated fatty acids such as EPA or ARA in free or bound form.
  • fatty acids derived from C18: 2 fatty acids such as GLA, DGLA or ARA or those derived from C18: 3 fatty acids derive, such as SDA, ETA or EPA.
  • linoleic acid LA, C18: 2 A9 '12
  • GLA, DGLA and ARA can arise as products of the process which may be present as free fatty acids or bound.
  • ⁇ -linolenic acid ALA, C18: 3 A9 ' 12 ' 15
  • SDA, ETA, EPA and / or DHA free fatty acids or bound as described above.
  • Enzymes ⁇ -5-desaturase, ⁇ -6-desaturase, ⁇ -4-desaturase, ⁇ -12-desaturase, ⁇ -5 elongase and / or ⁇ -6 elongase can be targeted in the abovementioned organisms advantageously in the abovementioned plants produced only individual products.
  • Due to the activity of ⁇ -6-desaturase and ⁇ -6 elongase for example, GLA and DGLA or SDA and ETA are formed, depending on the starting plant and unsaturated fatty acid. Preference is given to DGLA or ETA or mixtures thereof.
  • ARA, EPA and / or DHA are additionally produced.
  • ARA, EPA or DHA or mixtures thereof are synthesized, depending on the fatty acids present in the organism or in the plant, which serves as the starting substance for the synthesis. Since these are biosynthetic chains, the respective end products are not present as pure substances in the organisms. There are always small amounts of precursor compounds in the final product.
  • small amounts are less than 20 wt .-%, advantageously less than 15 wt .-%, more preferably less than 10 wt .-%, most preferably less than 5, 4, 3, 2 or 1 wt .-% based to the end product DGLA, ETA or mixtures thereof or ARA, EPA, DHA or mixtures thereof advantageously EPA or DHA or mixtures thereof.
  • the fatty acids can also be fed from the outside.
  • Preferred substrates are linoleic acid (C18: 2 A9 '12 ), ⁇ -linolenic acid (C18: 3 ⁇ 6 ' 9 '12 ), eicosadienoic acid (C20: 2 ⁇ 11 ' 14 ), dihomo- ⁇ -linolenic acid (C20: 3 ⁇ 8 ' 11 ' 14 ), the arachidonic acid (C20: 4 ⁇ 5A11 '14 ), the docosatetraenoic acid (C22: 4 ⁇ 7 ' 10 ' 13 ' 16 ) and the docosapentaenoic acid (C22: 5 ⁇ 4 ' 7 ' 10 ' 13 ' 15 ).
  • nucleic acid sequences or their derivative or homologs which code for polypeptides which still possess the enzymatic activity of the proteins encoded by nucleic acid sequences.
  • sequences are cloned individually or in combination with the polynucleotides of the invention in expression constructs and used for introduction and expression in organisms. By their construction, these expression constructs enable a favorable optimal synthesis of the polyunsaturated fatty acids produced in the process according to the invention.
  • the method further comprises the step of obtaining a cell or whole organism containing the nucleic acid sequences used in the method, wherein the cell and / or organism with a polynucleotide of the invention is a gene construct or a vector as described below, alone or in combination with other nucleic acid sequences coding for proteins of the fatty acid or lipid metabolism.
  • this method further comprises the step of recovering the oils, lipids or free fatty acids from the organism or from the culture.
  • the culture may be, for example, a fermentation culture, for example, in the case of culturing microorganisms such as e.g.
  • the cell or organism thus produced is advantageously a cell of an oil-producing organism such as an oil crop such as peanut, canola, canola, flax, hemp, peanut, soybean, safflower, hemp, sunflower or borage.
  • Cultivation is, for example, culturing in the case of plant cells, tissue or organs on or in a nutrient medium or the whole plant on or in a substrate, for example in hydroponics, potting soil or on arable land.
  • Suitable organisms or host cells for the process according to the invention are those which are able to synthesize fatty acids, especially unsaturated fatty acids, or are suitable for the expression of recombinant genes.
  • Examples include plants such as Arabidopsis, Asteraceae such as Calendula or crops such as soybean, peanut, castor, sunflower, corn, cotton, flax, rape, coconut, oil palm, dyer safflower (Carthamus tinctorius) or cocoa bean, microorganisms such as fungi, for example, the genus Mortierella, Thraustochytrium, Saprolegnia, Phytophthora or Pythium, bacteria such as the genus Escherichia or Shewanella, yeasts like the Genus Saccharomyces, cyanobacteria, ciliates, algae such as Mantoniella or Ostreococcus or protozoa such as dinoflagellates such as Thalassiosira or Crypthe
  • transgenic animals are also advantageously suitable for non-human animals, for example C. elegans. Other suitable host cells and organisms have previously been described in detail.
  • Transgenic plants which contain the polyunsaturated fatty acids synthesized in the process according to the invention can advantageously be marketed directly without the synthesized oils, lipids or fatty acids having to be isolated.
  • Plants in the process according to the invention include whole plants and all plant parts, plant organs or plant parts such as leaves, stems, seeds, roots, tubers, anthers, fibers, root hairs, stems, embryos, callosis, kotelydons, petioles, crop material, plant tissue, reproductive tissue, Cell cultures that can be derived from the transgenic plant and / or used to produce the transgenic plant.
  • the seed includes all seed parts such as the seed shells, epidermis and sperm cells, endosperm or embryonic tissue.
  • the compounds prepared in the process according to the invention can also be isolated from the organisms advantageously plants in the form of their oils, fat, lipids and / or free fatty acids.
  • Polyunsaturated fatty acids produced by this process can be harvested by harvesting the organisms either from the culture in which they grow or from the field. This can be done by pressing or extraction of the plant parts, preferably the plant seeds.
  • the oils, fats, lipids and / or free fatty acids can be obtained by so-called cold pressing or cold pressing without supplying heat by pressing.
  • the plant parts, especially the seeds, to be easier to digest they are first crushed, steamed or roasted. The pretreated seeds can then be pressed or extracted with solvents such as warm hexane.
  • the solvent is removed again.
  • these are harvested after harvesting, for example, directly without further working steps, or else extracted after digestion by various methods known to the person skilled in the art. In this way, more than 96% of the compounds prepared in the process can be isolated.
  • the products thus obtained are further processed, that is refined.
  • the so-called degumming can be carried out enzymatically or, for example, chemically / physically by adding acid, such as phosphoric acid.
  • the free fatty acids are removed by treatment with a base, for example sodium hydroxide solution.
  • the product obtained is thoroughly washed with water to remove the lye remaining in the product and dried.
  • the products are subjected to bleaching with, for example, bleaching earth or activated carbon.
  • the product is still deodorized, for example, with steam.
  • the PUFAs or LCPUFAs produced by this process are C 8 -, C 2 O- or C 22 -fatty acid molecules and advantageously C 2 o- or C 22 -fatty acid molecules having at least two double bonds in the fatty acid molecule, preferably three, four, five or six double bonds.
  • These Ci 8 -, C 2 o- or C 22 -Fettkladklaküle can be isolated from the organism in the form of an oil, lipid or a free fatty acid. Suitable organisms are, for example, those mentioned above. Preferred organisms are transgenic plants.
  • One embodiment of the invention is therefore oils, lipids or fatty acids or fractions thereof which have been prepared by the method described above, more preferably oil, lipid or fatty acid composition comprising PUFAs derived from transgenic plants.
  • oils, lipids or fatty acids advantageously contain 6 to 15% palmitic acid, 1 to 6% stearic acid as described above; 7 - 85% oleic acid; 0.5 to 8% of vaccenic acid, 0.1 to 1% of arachidic acid, 7 to 25% of saturated fatty acids, 8 to 85% of monounsaturated fatty acids and 60 to 85% of polyunsaturated fatty acids in each case based on 100% and on the total fatty acid content of the organisms.
  • polyunsaturated fatty acid in the fatty acid esters or fatty acid mixtures are preferably at least 0.1; 0.2; 0.3; 0.4; 0.5; 0.6; 0.7; 0.8; 0.9 or 1% based on the total fatty acid content of arachidonic acid.
  • the fatty acid esters or fatty acid mixtures prepared by the process according to the invention advantageously contain fatty acids selected from the group of the fatty acids erucic acid (13-docosaic acid), sterculic acid (9,10-methylene octadec-9-enoic acid), malvalic acid (8,9 -Methylene heptadec-8-enoic acid), chaulmoogric acid (cyclopentenodecanoic acid), furan fatty acid (9,12-epoxy-octadeca-9,11-dienoic acid), vernonic acid (9,10-epoxyoctadec-12-enoic acid), tartric acid ( 6- octadecynoic acid), 6-nonadecynoic acid, santalbic acid (t11-octadecen-9-ynoic acid), 6,9-octadecenynoic acid, pyrulic acid (t10-heptadecen
  • fatty acids are generally advantageously present only in traces in the fatty acid esters or fatty acid mixtures prepared by the process according to the invention, that is to say they are less than 30%, preferably less than 25%, 24%, 23%, based on the total fatty acids. , 22% or 21%, more preferably less than 20%, 15%, 10%, 9%, 8%, 7%, 6% or 5%, most preferably less than 4%, 3%, 2% or 1% ago.
  • the oils, lipids or fatty acids according to the invention preferably contain at least 0.5%, 1%, 2%, 3%, 4% or 5%, advantageously at least 6%, 7%, 8%, 9% or 10%, particularly advantageously at least 11%, 12%, 13%, 14% or 15% ARA or at least 0.5%, 1%, 2%, 3%, 4% or 5%, advantageously at least 6%, or 7%, more preferably at least 8 %, 9% or 10% EPA and / or DHA based on the total fatty acid content of the production organism advantageously a plant, particularly advantageous an oil crop such as soy, rapeseed, coconut, oil palm, safflower, flax, hemp, castor, calendula, peanut, cocoa bean , Sunflower or the above-mentioned other monocotyledonous or dicotyledonous oil crops.
  • an oil crop such as soy, rapeseed, coconut, oil palm, safflower, flax, hemp, cast
  • Another embodiment of the invention is the use of the oil, lipid, fatty acids and / or fatty acid composition in feed, food, cosmetics or pharmaceuticals.
  • the oils, lipids, fatty acids or fatty acid mixtures according to the invention may be mixed with other oils, lipids, fatty acids or fatty acid mixtures of animal origin, such as those described in the art, for example. Fish oils are used. These oils, lipids, fatty acids or fatty acid mixtures, which consist of vegetable and animal components, can be used for the production of feed, food, cosmetics or pharmaceuticals.
  • oil is understood as meaning a fatty acid mixture which contains unsaturated, saturated, preferably esterified fatty acid (s). It is preferred that the oil, lipid or fat contain a high proportion of polyunsaturated free or advantageously esterified fatty acid (s), in particular linoleic acid, ⁇ -linolenic acid, dihomo- ⁇ -linolenic acid, arachidonic acid, ⁇ -linolenic acid, stearidonic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosapentaenoic acid or docosahexaenoic acid.
  • s polyunsaturated free or advantageously esterified fatty acid
  • the proportion of unsaturated esterified fatty acids is about 30%, more preferred is a proportion of 50%, even more preferred is a proportion of 60%, 70%, 80% or more.
  • the proportion of fatty acid after conversion of the fatty acids into the methyl esters can be determined by transesterification by gas chromatography.
  • the oil, lipid or fat may contain various other saturated or unsaturated fatty acids, eg calendulic acid, palmitic, palmitoleic, stearic, oleic acid, etc. In particular, depending on the starting organism, the proportion of the various fatty acids in the oil or fat may vary.
  • the polyunsaturated fatty acids having advantageously at least two double bonds which are produced in the process are, as described above, for example sphingolipids, phosphoglycerides, lipids, glycolipids, phospholipids, monoacylglycerol, diacylglycerol, triacylglycerol or other fatty acid esters.
  • the polyunsaturated fatty acids containing, for example, an alkali treatment such as aqueous KOH or NaOH or acid hydrolysis advantageously in the presence of an alcohol such as methanol or ethanol or via an enzymatic cleavage liberate and isolate via, for example, phase separation and subsequent acidification via, for example, H 2 SO 4 .
  • an alkali treatment such as aqueous KOH or NaOH or acid hydrolysis
  • an alcohol such as methanol or ethanol or via an enzymatic cleavage
  • the release of the fatty acids can also be carried out directly without the workup described above.
  • the nucleic acids used in the method can advantageously be either a plant cell or plant, either on a separate plasmid or advantageously integrated into the genome of the host cell.
  • integration may be at random or by such recombination as replacing the native gene with the incorporated copy, thereby modulating production of the desired compound by the cell, or by using a gene in "trans".
  • the nucleic acids are introduced into the organisms via multi-expression cassettes or constructs for multiparallel expression advantageous for multiparallel seed-specific expression of genes brought into the plants.
  • Moose and algae are the only known plant systems that produce significant amounts of polyunsaturated fatty acids, such as arachidonic acid (ARA) and / or eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA).
  • nucleic acid molecules which are isolated from strains which also accumulate PUFAs in the triacylglycerol fraction are particularly advantageous for the process according to the invention and thus for modification of the lipid and PUFA production system in a host, in particular plants, such as oilseed plants, for example Rapeseed, canola, flax, hemp, soy, sunflower, borage. They are therefore advantageous for use in the process according to the invention.
  • acyl-CoA-dehydrogenase s
  • acyl-ACP [acyl carrier protein] desaturase
  • acyl-ACP thioesterase s
  • Fatty acid acyltransferase s
  • acyl-CoA lysophospholipid acyltransferase
  • fatty acid synthase s
  • fatty acid hydroxylase s
  • acetyl coenzyme A carboxylase s
  • acyl coenzyme A- Oxidase s
  • fatty acid desaturase s
  • fatty acid acetylenase s
  • lipoxygenase s
  • the polyunsaturated C 16 -fatty acids must first be desaturated by the enzymatic activity of a desaturase and then be extended by at least two carbon atoms via an elongase. After one round of elongation this enzyme activity leads to C 2 o-fatty acids, and after two rounds of elongation to C 22 -fatty acids.
  • Desaturases and elongases used in the activity of the process according to the invention preferably leads to Ci ⁇ -, C 2 0 and / or C 22 fatty acids advantageously having at least two double bonds in the fatty acid molecule, preferably with three, four, five or six double bonds, especially preferably C 2 o- and / or C 22 -fatty acids having at least two double bonds in the fatty acid molecule, preferably having three, four, five or six double bonds, very particularly preferably having five or six double bonds in the molecule.
  • further desaturation and elongation steps such as desaturation at ⁇ -5 and ⁇ -4 positions may occur.
  • Particularly preferred products of the process according to the invention are dihomo- ⁇ -linolenic acid, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid and / or docosaheic acid.
  • the C 2 o fatty acids having at least two double bonds in the fatty acid can be extended by the enzymatic activity according to the invention in the form of the free fatty acid or in the form of the esters, such as phospholipids, glycolipids, sphingolipids, phosphoglycerides, monoacylglycerol, diacylglycerol or triacylglycerol.
  • the preferred biosynthesis site of fatty acids, oils, lipids or fats in the advantageously used plants is, for example, generally the seeds or cell layers of the seed, so that a seed-specific expression of the nucleic acids used in the method is useful.
  • biosynthesis of fatty acids, oils or lipids need not be limited to the seed tissue, but may also be tissue-specific in all other parts of the plant - for example in epidermal cells or in the tubers.
  • microorganisms such as yeasts such as Saccharomyces or Schizosaccharomyces
  • fungi such as Mortierella, Aspergillus, Phytophtora, Entomophthora, Mucor or Thraustochytrium algae such as Isochrysis, Mantoniella, Ostreococcus, Phaeodactylum or Crypthecodiniu
  • yeasts such as Saccharomyces or Schizosaccharomyces
  • fungi such as Mortierella, Aspergillus, Phytophtora, Entomophthora, Mucor or Thraustochytrium algae such as Isochrysis, Mantoniella, Ostreococcus, Phaeodactylum or Crypthecodiniu
  • these organisms are advantageously attracted to fermentation.
  • the polyunsaturated fatty acids prepared in the process can be at least 5%, preferably at least 10%, more preferably at least 20%, very particularly preferably at least 50%. be increased compared to the wild type of organisms that do not contain the nucleic acids recombinantly.
  • the polyunsaturated fatty acids produced in the organisms used in the process can in principle be increased in two ways.
  • the pool of free polyunsaturated fatty acids and / or the proportion of esterified polyunsaturated fatty acids produced by the process can be increased.
  • the process according to the invention increases the pool of esterified polyunsaturated fatty acids in the transgenic organisms.
  • microorganisms are used as organisms in the process according to the invention, they are grown or grown, depending on the host organism, in a manner known to the person skilled in the art.
  • Microorganisms are usually in a liquid medium containing a carbon source usually in the form of sugars, a nitrogen source usually in the form of organic nitrogen sources such as yeast extract or salts such as ammonium sulfate, trace elements such as iron, manganese, magnesium salts and optionally contains vitamins, at temperatures between 0 0 C and 10O 0 C, preferably between 10 0 C to 60 ° C attracted under oxygen fumigation.
  • the pH of the nutrient fluid can be kept at a fixed value, that is regulated during the cultivation or not.
  • the cultivation can be batchwise, semi-batch wise or continuous. Nutrients can be presented at the beginning of the fermentation or fed in semi-continuously or continuously.
  • the polyunsaturated fatty acids prepared can be isolated from the organisms by methods known to those skilled in the art as described above. For example, extraction, distillation, crystallization, optionally salt precipitation and / or chromatography. The organisms can be opened up for this purpose yet advantageous.
  • the inventive method when it is in the host organisms are microorganisms, advantageously carried out at a temperature between 0 0 C to 95 °, preferably between 10 0 C to 85 ° C, more preferably between 15 ° C to 75 ° C, most preferably carried out between 15 ° C to 45 ° C.
  • the pH is advantageously maintained between pH 4 and 12, preferably between pH 6 and 9, more preferably between pH 7 and 8.
  • the process according to the invention can be operated batchwise, semi-batchwise or continuously.
  • a summary of known cultivation methods is in the textbook by Chmiel (Bioreatechnik 1. Introduction to bioprocess engineering (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (bioreactors and peripheral facilities (Vieweg Verlag, Braunschweig / Wiesbaden, 1994)) Find.
  • the culture medium to be used must suitably satisfy the requirements of the respective strains. Descriptions of culture media of various microorganisms are contained in the Manual of Methods for General Bacteriology of the American Society for Bacteriology (Washington D.C, USA, 1981).
  • these media which can be used according to the invention usually comprise one or more carbon sources, nitrogen sources, inorganic salts, vitamins and / or trace elements.
  • Preferred carbon sources are sugars, such as mono-, di- or polysaccharides.
  • sugars such as mono-, di- or polysaccharides.
  • very good carbon sources are glucose, fructose, mannose, galactose, ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, starch or cellulose.
  • Sugar can also be added to the media via complex compounds, such as molasses, or other by-products of sugar refining. It can also be advantageous to add mixtures of different carbon sources.
  • oils and fats such as soybean oil, sunflower oil, peanut oil and / or coconut oil, fatty acids such as palmitic acid, stearic acid and / or linoleic acid, alcohols and / or polyalcohols such.
  • fatty acids such as palmitic acid, stearic acid and / or linoleic acid
  • alcohols and / or polyalcohols such as glycerol, methanol and / or ethanol and / or organic acids such as acetic acid and / or lactic acid.
  • Nitrogen sources are usually organic or inorganic nitrogen compounds or materials containing these compounds.
  • Exemplary nitrogen sources include ammonia in liquid or gas form or ammonium salts such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate or ammonium nitrate, nitrates, urea, amino acids or complex nitrogen sources such as corn steep liquor, soybean meal, soy protein, yeast extract, meat extract and others.
  • the nitrogen sources can be used singly or as a mixture.
  • Inorganic salt compounds which may be included in the media include the chloride, phosphorus or sulfate salts of calcium, magnesium, sodium, cobalt, molybdenum, potassium, manganese, zinc, copper and iron.
  • sulfur-containing fine chemicals in particular methionine
  • inorganic sulfur-containing compounds such as sulfates, sulfites, dithionites, tetrathionates, thiosulfates, sulfides but also organic sulfur compounds, such as mercaptans and thiols can be used.
  • Phosphoric acid potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts can be used as the phosphorus source.
  • Chelating agents can be added to the medium to keep the metal ions in solution.
  • Particularly suitable chelating agents include dihydroxyphenols, such as catechol or protocatechuate, or organic acids, such as citric acid.
  • the fermentation media used according to the invention for the cultivation of microorganisms usually also contain other growth factors, such as vitamins or growth promoters, which include, for example, biotin, riboflavin, thiamine, folic acid, nicotinic acid, panthothenate and pyridoxine.
  • Growth factors and salts are often derived from complex media components, such as yeast extract, molasses, corn steep liquor, and the like.
  • suitable precursors can be added to the culture medium.
  • the exact composition of the media compounds will depend heavily on the experiment and will be specific to each specific see case individually decided. Information about the media optimization is available from the textbook "Applied Microbiol Physiology, A Practical Approach” (Ed PM Rhodes, PF Stanbury, IRL Press (1997) pp. 53-73, ISBN 0 19 963577 3).
  • Growth media may also be obtained from commercial suppliers such as Standard 1 (Merck) or BHI (Brain heart infusion, DIFCO) and the like.
  • All media components are sterilized either by heat (20 min at 1, 5 bar and 121 0 C) or by sterile filtration.
  • the components can either be sterilized together or, if necessary, sterilized separately. All media components may be present at the beginning of the culture or added randomly or batchwise, as desired.
  • the temperature of the culture is usually between 15 ° C and 45 ° C, preferably at 25 ° C to 40 0 C and can be kept constant or changed during the experiment.
  • the pH of the medium should be in the range of 5 to 8.5, preferably around 7.0.
  • the pH for cultivation can be controlled during cultivation by addition of basic compounds such as sodium hydroxide, potassium hydroxide, ammonia or ammonia water or acidic compounds such as phosphoric acid or sulfuric acid.
  • acidic compounds such as phosphoric acid or sulfuric acid.
  • the foaming anti-foaming agents such.
  • As fatty acid polyglycol are used.
  • the medium can be selected selectively acting substances such. As antibiotics, are added.
  • oxygen or oxygen-containing gas mixtures such as ambient air
  • the temperature of the culture is nor- mally at 20 0 C to 45 ° C and preferably 25 ° C to 40 0 C.
  • the culture is continued until a maximum of the desired product has formed. This goal is usually reached within 10 hours to 160 hours.
  • the fermentation broths thus obtained in particular containing polyunsaturated fatty acids, usually have a dry matter content of 7.5 to 25% by weight.
  • the fermentation broth can then be further processed.
  • the biomass can be wholly or partly by separation methods, such. As centrifugation, filtration, decantation or a combination of these methods are removed from the fermentation broth or completely left in it.
  • the biomass is worked up after separation.
  • the fermentation broth can also without cell separation with known methods such. B. with the aid of a rotary evaporator, thin film evaporator, falling film evaporator, by reverse osmosis, or by nanofiltration, thickened or be concentrated. This concentrated fermentation broth may eventually be worked up to recover the fatty acids contained therein.
  • polynucleotides or polypeptides of the present invention which are involved in the metabolism of lipids and fatty acids, PUFA cofactors and enzymes or in the transport of lipophilic compounds via membranes, are advantageously used in plants according to the invention for modulating the production of PUFAs in transgenic organisms
  • Solanacaen - plants such as potato, tobacco, aubergine and tomato, Vicia species, pea, cassava, alfalfa, bush plants (coffee, cocoa, tea), Salix species, trees (oil palm, coconut) and perennial grasses and forage crops, either directly ( For example, if overexpression or optimization of a fatty acid biosynthesis protein has a direct impact on
  • PUFAs polyunsaturated fatty acids
  • Brasicaceae for example stearidonic acid, eicosapentaenoic acid and docosahexaenoic acid
  • Brasicaceae for example stearidonic acid, eicosapentaenoic acid and docosahexaenoic acid
  • boraginaceous plants for example stearidonic acid, eicosapentaenoic acid and docosahexaenoic acid
  • linaceae particularly advantageous is Lein (Linum usitatissimum) for the production of PUFAS with the nucleic acid sequences of the invention advantageously, as described, in combination with other desaturases and elongases.
  • the lipid synthesis can be divided into two sections: the synthesis of fatty acids and their attachment to sn-glycerol-3-phosphate and the addition or modification of a polar head group.
  • Common lipids used in membranes include phospholipids, glycolipids, sphingolipids and phosphoglycerides. The OO
  • Fatty acid synthesis begins with the conversion of acetyl-CoA into malonyl-CoA by the acetyl-CoA carboxylase or into acetyl-ACP by the acetyl transacylase. After a condensation reaction, these two product molecules together form acetoacetyl-ACP, which is converted via a series of condensation, reduction and dehydration reactions, so that a saturated fatty acid molecule with the desired chain length is obtained.
  • the production of unsaturated fatty acids from these molecules is catalyzed by specific desaturases, either aerobically by molecular oxygen or anaerobically (for fatty acid synthesis in microorganisms see FC Neidhardt et al., (1996) E.
  • fatty acids thus bound to phospholipids must then be converted again for the further elongations from the phospholipids into the fatty acid CoA ester pool. This is facilitated by acyl-CoA3sophospholipid acyltransferases. Furthermore, these enzymes can transfer the elongated fatty acids again from the CoA esters to the phospholipids. This reaction sequence can optionally be run through several times.
  • Precursors for the PUFA biosynthesis are, for example, oleic acid, linoleic acid and linolenic acid. These Ci ⁇ -carbon fatty acids must be extended to C 2 o and C 22 in order to obtain fatty acids of the eicosa- and docosa-chain type.
  • the desaturases used in the process such as the ⁇ -12, ⁇ -4, ⁇ -5 and ⁇ -6 desaturases and / or the ⁇ -5, ⁇ -6 elongases, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid or Docosahexaen Anlagenre advantageously eicosapentaenoic acid and / or docosahexaenoic acid are prepared and then used for various purposes in food, feed, cosmetic or pharmaceutical applications.
  • C 2 - and / or C 22 -fatty acids having at least two, preferably at least three, four, five or six double bonds in the fatty acid molecule, preferably C 2 0 or C 22 -fatty acids with advantageously four, five or six double bonds, can be used with the abovementioned enzymes be prepared in the fatty acid molecule.
  • the desaturation can take place before or after elongation of the corresponding fatty acid.
  • the products of desaturase activities and possible further desaturation and elongation result in preferred PUFAs having a higher degree of desaturation, including a further elongation of C 20 to C 22 fatty acids, to fatty acids such as ⁇ -linolenic acid, dihomo- ⁇ -linolenic acid, arachidonic acid, Stearidonic acid, eicosatetraenoic acid or eicosapentaenoic acid.
  • Substrates of the desaturases and elongases used in the process of this invention are C 1 6-, C linolenic dihomo- ⁇ -1 8- or C2o fatty acids such as linoleic acid, ⁇ -linolenic acid, ⁇ -linolenic acid, Eicosatetraenoic acid or stearidonic acid.
  • Preferred substrates are linoleic acid, v-linolenic acid and / or ⁇ -linolenic acid, dihomo- ⁇ -linolenic acid or arachidonic acid, eicosatetraenoic acid or eicosapentaenoic acid.
  • the synthesized C 2 o- or C 22 -fatty acids with at least two, three, four, five or six double bonds in the fatty acid are obtained in the process according to the invention in the form of the free fatty acid or in the form of their esters, for example in the form of their glycerides.
  • glycolide is understood to mean a glycerol esterified with one, two or three carboxylic acid residues (mono-, di- or triglyceride).
  • glycolide is also meant a mixture of different glycerides.
  • the glyceride or glyceride mixture may contain other additives, e.g. contain free fatty acids, antioxidants, proteins, carbohydrates, vitamins and / or other substances.
  • a "glyceride” in the sense of the method according to the invention is also understood to mean derivatives derived from glycerol.
  • these also include glycerophospholipids and glyceroglycolipids.
  • the glycerophospholipids such as lecithin (phosphatidylcholine), cardiolipin, phosphatidylglycerol, phosphatidylserine and alkylacylglycerophospholipids, may be mentioned by way of example here.
  • fatty acids must then be transported to various modification sites and incorporated into the triacylglycerol storage lipid.
  • Another important step in lipid synthesis is the transfer of fatty acids to the polar head groups, for example by glycerol-fatty acid acyltransferase (see Frentzen, 1998, Lipid, 100 (4-5): 161-166).
  • the PUFAs produced in the process comprise a group of molecules that are no longer able to synthesize, and therefore need to take up, higher animals, or that can no longer sufficiently produce higher animals themselves, and thus have to additionally take up, even though they are readily synthesized by other organisms, such as bacteria For example, cats can no longer synthesize arachidonic acid.
  • phospholipids are to be understood as meaning phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol and / or phosphatidylinositol, advantageously phosphatidylcholine.
  • production or productivity are known in the art and include the concentration of the fermentation product (compounds of formula I) formed in a given period of time and fermentation volume (e.g., kg of product per hour per liter). It also includes productivity within a plant cell or plant, that is, the content of the desired fatty acids produced in the process based on the content of all fatty acids in that cell or plant.
  • the term efficiency of production includes the time required to achieve a certain amount of production (e.g., how long the cell takes to establish a given throughput rate of a fine chemical).
  • yield or product / carbon yield is known in the art and includes the efficiency of converting the carbon source into the product (i.e., the fine chemical). This is usually expressed, for example, as kg of product per kg of carbon source.
  • biosynthesis or biosynthetic pathway are known in the art and involve the synthesis of a compound, preferably an organic compound, by a cell from intermediates, for example in a multi-step and highly regulated process.
  • degradation or degradation pathway are well known in the art and involve the cleavage of a compound, preferably an organic compound, by a cell into degradation products (more generally, smaller or less complex molecules), for example in a multi-step and highly regulated process.
  • metabolism is known in the art and includes the entirety of the biochemical reactions that take place in an organism.
  • the metabolism of a particular compound e.g., the metabolism of a fatty acid
  • the metabolism of a particular compound then comprises all of the biosynthetic, modification, and degradation pathways of that compound in the cell that affect that compound.
  • the yield, production and / or efficiency of the production of the polyunsaturated fatty acids in a plant, preferably in an oil crop, or a microorganism can be influenced.
  • the number or activity of the polypeptides or polynucleotides according to the invention can be increased, so that larger amounts of the gene products and thus ultimately larger amounts of the compounds of general formula I are produced. Also, a de novo synthesis in an organism lacking the activity and ability to biosynthesize the compounds before introducing the gene (s) of interest is possible.
  • a polynucleotide according to the invention By introducing a polynucleotide according to the invention into an organism alone or in combination with other genes into a cell, not only can the biosynthesis flux to the end product be increased, but also the corresponding triacylglycerol composition can be increased or created de novo. Likewise, the number or activity of other genes necessary for the import of nutrients necessary for the biosynthesis of one or more fatty acids, oils, polar and / or neutral lipids may be increased, such that the concentration of these precursors, cofactors or intermediates within the cells or within the storage compartment, thereby further increasing the ability of the cells to produce PUFAs.
  • fatty acids obtained in the process are suitable as starting material for the chemical synthesis of other valuable products. They may be used, for example, in combination with each other or solely for the manufacture of pharmaceuticals, foods, animal feed or cosmetics.
  • the invention also encompasses a process for preparing an oil, lipid or fatty acid composition. send relates to the steps of the method according to the invention and the further step of formulating the substance as an oil, lipid or fatty acid composition.
  • the oil, lipid or fatty acid composition is further formulated into a medicament, a cosmetic, a food, a feed, preferably a fish feed, or a dietary supplement.
  • the invention generally relates to the use of the polynucleotide, the vector, the host cell, the polypeptide or the transgenic, non-human organism of the present invention for the preparation of an oil, lipid or fatty acid composition. This is then preferably used as pharmaceuticals, cosmetics, foods, animal feed, preferably fish feed, or dietary supplements.
  • FIG. 1 shows a sequence comparison of the ⁇ 5 and ⁇ 6 elongase amino acid sequences from O. lucimarinus, O. tauri and T. pseudonana in the ClustalW comparison.
  • FIG. 2 shows a sequence comparison of the ⁇ 4-desaturase amino acid sequences from O. lucimarinus, O. tauri and T. pseudonana in the ClustalW comparison.
  • FIG. 3 shows a sequence comparison of the ⁇ 5-desaturase amino acid sequences from O. lucimarinus, O. tauri and T. pseudonana in the ClustalW comparison.
  • FIG. 4 shows a sequence comparison of the ⁇ 6-desaturase amino acid sequences from O. lucimarinus, O. tauri and T. pseudonana in the ClustalW comparison.
  • FIG. 5 shows a sequence comparison of the ⁇ 12-desaturase amino acid sequences from O. lucimarinus, O. tauri and T. pseudonana in the ClustalW comparison.
  • FIG. 6 shows the gas chromatographic determination of the fatty acids from yeasts which have been transformed with the plasmid pYES (A, B) or pYES-D5Elo (OI) (C). The fatty acid 20: 4 ⁇ 5, 8, 1, 14 was fed (B, C).
  • FIG. 7 shows the gas chromatographic determination of the fatty acids from yeasts which have been transformed with the plasmid pYES (A, B, C) or pYES-D ⁇ EIo (OI) (D, E).
  • the fatty acids 18: 3 ⁇ 6,9,12 and 18: 4 ⁇ 6,9, 12,15 were fed (B, D) and (C, E), respectively.
  • FIG. 8 shows the gas chromatographic determination of the fatty acids from yeasts which have been transformed with the plasmid pYES (A, B) or pYES-D5Des (OI_2) (C).
  • the fatty acids 20: 3 ⁇ 5, 8, 1, 14 were fed into (B) and (C).
  • FIG. 9 shows the gas chromatographic determination of the fatty acids from yeasts which have been transformed with the plasmid pYES (A) or pYES-D12Des (OI) (B).
  • FIG. 10 shows the gas chromatographic determination of the fatty acids from yeast.
  • the cloning methods e.g. Restriction cleavage, agarose gel electrophoresis, purification of DNA fragments, transfer of nucleic acids to nitrocellulose and nylon membranes, linkage of DNA fragments, transformation of Escherichia coli cells, culture of bacteria and sequence analysis of recombinant DNA were performed as described in Sambrook et al. (1989) (CoId Spring Harbor Laboratory Press: ISBN 0-87969-309-6).
  • Example 2 Sequence Analysis of Recombinant DNA
  • the sequencing of recombinant DNA molecules was carried out with a laser fluorescence DNA sequencer from ABI according to the method of Sanger (Sanger et al. (1977) Proc. Natl. Acad. See, USA74, 5463-5467). Fragments resulting from a polymerase chain reaction were sequenced and checked to avoid polymerase errors in constructs to be expressed.
  • the effect of genetic modification in plants, fungi, algae, ciliates or on the production of a desired compound may be determined by cultivating the modified microorganism or modified plant under suitable conditions (such as those described above), and Medium and / or the cellular components on the increased production of the desired product (ie of lipids or a fatty acid) is examined.
  • suitable conditions such as those described above
  • These analytical techniques are well known to those skilled in the art and include spectroscopy, thin layer chromatography, staining methods of various types, enzymatic and microbiological methods, and analytical chromatography such as high performance liquid chromatography (see, for example, Ullman, Encyclopedia of Industrial Chemistry, Vol. A2, pp. 89-90 and p. 443-613, VCH: Weinheim (1985); Fallon, A., et al.
  • FAME fatty acid methyl ester
  • GC-MS gas-liquid chromatography-mass spectrometry
  • TAG triacylglycerol
  • TLC thin-layer chromatography
  • the unambiguous evidence for the presence of fatty acid products can be obtained by analysis of recombinant organisms by standard analytical methods: GC, GC-MS or TLC as variously described by Christie and the references therein (1997, in: Advances on Lipid Methodology, Fourth Edition. Christie, Oliver Press, Dundee, 119-169, 1998, Gas Chromatography Mass Spectrometry Method, Lipids 33: 343-353).
  • the material to be analyzed may be broken up by sonication, milling in the glass mill, liquid nitrogen and milling or other applicable methods.
  • the material must be centrifuged after rupture.
  • the sediment is distilled in aqua. re-suspended, heated at 100 ° C. for 10 minutes, cooled on ice and recentrifuged, followed by extraction into 0.5 M sulfuric acid in methanol with 2% dimethoxypropane for 1 hour at 90 ° C., resulting in hydrolyzed oil and lipid compounds, which give transmethylated lipids.
  • FIG. 1 shows the sequence similarities to other algae (Ostreococcus tauri, Thalassiosira pseudonana) for the different elongase amino acid sequences in the ClustalW sequence comparison. Surprisingly, the sequences of O. lucimarinus differ significantly in their amino acid sequence from the other algae.
  • the cloning was carried out as follows:
  • the conditions for the PCR were as follows: first denaturation at 95 ° C for 5 minutes, followed by 30 cycles at 94 ° C for 30 seconds, 55 ° C for 1 minute and 72 ° C for 2 minutes and a final extension step at 72 ° C for 10 minutes.
  • the open reading frames of the respective DNAs are cloned downstream of the galactose-inducible GAL1 promoter of pYES2.1A / 5-His-TOPO (Invitrogen) to yield pOLE1 and pOLE2.
  • the Saccharomyces cerev / s / ae strain 334 is transformed by electroporation (1500 V) with the vector pOLE1 or pOLE2, respectively.
  • a yeast is used, which is transformed with the empty vector pYES2.
  • the selection of the transformed yeasts is carried out on complete minimal medium (CMdum) agar plates with 2% glucose, but without uracil. After selection, three transformants each are selected for further functional expression.
  • CMdum liquid medium For the expression of the oil elongases, first precultures each of 5 ml of CMdum liquid medium with 2% (w / v) raffinose but without uracil are inoculated with the selected transformants and incubated for 2 days at 30 ° C., 200 rpm. 5 ml of CMdum liquid medium (without uracil) with 2% raffinose and 300 ⁇ M of various fatty acids are then inoculated with the precultures to an OD 6 oo of 0.05. Expression is induced by the addition of 2% (w / v) galactose. The cultures were incubated for a further 96 h at 20 ° C.
  • Yeasts transformed with plasmids pYES2, pOLE1 and pOLE2 are analyzed as follows:
  • the yeast cells from the major cultures are harvested by centrifugation (100 xg, 5 min, 20 ° C) and washed with 100 mM NaHCO 3 , pH 8.0 to remove residual medium and fatty acids.
  • fatty acid methyl esters (FAMEs) are produced by acid methanolysis.
  • the cell sediments are incubated with 2 ml of 1N methanolic sulfuric acid and 2% (v / v) dimethoxypropane for 1 h at 80 ° C.
  • Extraction of the FAMES is carried out by extracting twice with petroleum ether (PE).
  • the organic phases are distilled once each with 2 ml of 100 mM NaHCO 3 , pH 8.0 and 2 ml of distilled water. washed. Subsequently, the PE phases were dried with Na 2 SO 4 , evaporated under argon and taken up in 100 ⁇ l of PE. The samples are separated on a DB-23 capillary column (30 m, 0.25 mm, 0.25 ⁇ m, Agilent) in a Hewlett-Packard 6850 gas chromatograph with flame ionization detector.
  • the conditions for the GLC analysis are as follows: The oven temperature was programmed from 50 ° C to 250 ° C at a rate of 5 ° C / min and finally 10 min at 250 ° C (hold). The signals are identified by comparison of the retention times with corresponding fatty acid standards (Sigma).
  • the methodology is described, for example, in Napier and Michaelson, 2001, Lipids. 36 (8): 761-766; Sayanova et al., 2001, Journal of Experimental Botany. 52 (360): 1581-1585, Sperling et al., 2001, Arch. Biochem. Biophys. 388 (2): 293-298 and Michaelson et al., 1998, FEBS Letters. 439 (3): 215-218.
  • d5Elo various fatty acids were fed (Table 3).
  • the lined substrates are to be detected in large quantities in all transgenic yeasts.
  • the transgenic yeasts show the synthesis of new fatty acids, the products of the d5Elo (OI) reaction. This means that the gene d5Elo (OI) has been functionally expressed.
  • FIG. 6 shows the chromatograms of the individual experiments.
  • yeasts transformed with pYES without addition of fatty acids were analyzed in FIG. 6A.
  • Fig. 1B the yeast was transformed with pYES the fatty acid 20: 4 ⁇ 5, 8, 1, 14 fed. In this case, the fed fatty acid can be detected in large quantities.
  • Fig. 6C yeasts transformed with the plasmid pYES-D5Elo (OI).
  • OI plasmid pYES-D5Elo
  • an additional fatty acid can be detected in the yeasts with pYES-D5Elo (OI), which must be due to the activity of the D5Elo (OI). Based on the activity, D5Elo (OI) can be characterized as a ⁇ 5 elongase.
  • D5Elo (OI) SEQ ID12 was functionally expressed and possesses elongase activity. Based on the fed fatty acid, D5Elo (OI) can be characterized as a ⁇ 5 elongase, ie C20 fatty acids with a ⁇ 5 double bond are specifically extended. Activity and Substrate Determination of D6Elo (OI):
  • D6Elo D6Elo
  • various fatty acids were fed (Table 4).
  • the lined substrates are to be detected in large quantities in all transgenic yeasts.
  • the transgenic yeasts show the synthesis of new fatty acids, the products of the D6Elo (OI) reaction. This means that the gene D6Elo (OI) has been functionally expressed.
  • FIG. 7 shows the chromatograms of the individual experiments.
  • yeasts transformed with pYES without addition of fatty acids were analyzed in FIG. 7A.
  • Figs. 7B and 7C the yeasts transformed with pYES were added with the fatty acid 18: 3 ⁇ 6, 9, 12 (B) and 18: 4 ⁇ 6, 9, 12, 15 (C), respectively.
  • the fed fatty acid can be detected in large quantities.
  • Figs. 7C and 7D for yeasts transformed with the plasmid pYES-D ⁇ EIo (OI).
  • OI EIo
  • an additional fatty acid can be detected in the yeasts with pYES-D ⁇ EIo (OI), which must be due to the activity of the D6Elo (OI). Based on the activity D6Elo (OI) can be characterized as ⁇ 6 elongase.
  • D6Elo (OI) SEQ ID16 was functionally expressed and possesses elongase activity. Based on the fed fatty acid, D6Elo (OI) can be characterized as a ⁇ 6 elongase, ie C18 fatty acids with a ⁇ 6 double bond are specifically extended.
  • the Saccharomyces cerev / s / ae strain 334 is transformed by electroporation (1500 V) with the vector pYES2.1-d6Elo (OI).
  • a yeast was used, which is transformed with the empty vector pYES2.
  • the selection of the transformed yeasts is carried out on complete minimal medium (CMdum) agar plates with 2% glucose, but without uracil. After selection, three transformants each are selected for further functional expression.
  • d6Elo (OI) desaturase first precultures from 5 ml of CMdum liquid medium with 2% (w / v) raffinose but without uracil are inoculated with the selected transformants and incubated for 2 days at 30 0 C, 200 rpm. 5 ml CMdum liquid medium (without uracil) with 2% raffinose and 300 ⁇ M different fatty acids are then inoculated with the precultures to an OD 6 oo of 0.05. Expression is induced by the addition of 2% (w / v) galactose. The cultures are incubated for a further 96 h at 20 ° C.
  • Figures 2 to 5 show the sequence similarities to other algae (Ostreococcus tauri, Thalassiosira pseudonana) for the different desaturase amino acid sequences in ClustalW sequence comparison. Surprisingly, the sequences of O. lucimarinus differ significantly in their amino acid sequence from the other algae.
  • yeast cells For expression of the desaturases in yeast cells, they are harvested from the main cultures by centrifugation (100 ⁇ g, 5 min, 20 ° C.) and washed with 100 mM NaHCO 3 , pH 8.0 to remove residual medium and fatty acids. The yeast cell pellets are extracted with chloroform / methanol (1: 1) for 4 h. The resulting organic phase is extracted with 0.45% NaCl, dried with Na 2 SC> 4 and evaporated under vacuum.
  • the lipid extract is further purified by thin-layer chromatography (horizontal tank, chloroform: methanol: acetic acid 65: 35: 8) into the lipid classes phosphatidylcholine (PC), phosphatidiylinositol (PI), phosphatidyserine (PS), phosphatidylethanolamine (PE) and neutral Lipids (NL) separated.
  • PC phosphatidylcholine
  • PI phosphatidiylinositol
  • PS phosphatidyserine
  • PE phosphatidylethanolamine
  • NL neutral Lipids
  • the cell sediments are incubated with 2 ml of 1N methanolic sulfuric acid and 2% (v / v) dimethoxypropane for 1 h at 80 ° C.
  • the extraction of the FAMES was carried out by extraction twice with petroleum ether (PE).
  • PE petroleum ether
  • the organic phase is distilled once each with 2 ml of 100 mM NaHCO 3, pH 8.0 and 2 ml of distilled water. washed.
  • the PE phases are dried with Na 2 SO 4 , evaporated under argon and taken up in 100 ⁇ l of PE.
  • the samples are separated on a DB-23 capillary column (30 m, 0.25 mm, 0.25 ⁇ m, Agilent) in a Hewlett-Packard 6850 gas chromatograph with flame ionization detector.
  • the conditions for the GLC analysis are as follows: The oven temperature is from 50 0 C to 250 ° C at a rate of 5 ° C / min and finally 10 min at 250 ° C (hold) programmed.
  • the signals are identified by comparison of the retention times with corresponding fatty acid standards (Sigma).
  • the methodology is described, for example, in Napier and Michaelson, 2001, Lipids. 36 (8) 761-766; Sayanova et al., 2001, Journal of Experimental Botany. 52 (360): 1581-1585, Sperling et al., 2001, Arch. Biochem. Biophys. 388 (2): 293-298 and Michaelson et al., 1998, FEBS Letters. 439 (3): 215-218.
  • D5Des_2 (Ol) SEQ ID 24 To determine the activity and substrate specificity of D5Des_2 (Ol) SEQ ID 24, various fatty acids were fed (Table 7). The lined substrates are to be detected in large quantities in all transgenic yeasts. The transgenic yeasts show the synthesis of new fatty acids, the products of the D5Des_2 (Ol) reaction. This means that the gene D5Des_2 (Ol) has been functionally expressed.
  • Table 7 Administration / Implementation of Different Fatty Acids by D5Des OI 2).
  • FIG. 8 shows the chromatograms of the individual experiments.
  • yeasts transformed with pYES were analyzed in Fig. 8A without addition of fatty acids.
  • Fig. 8B the yeasts transformed with pYES were added the fatty acid 20: 3 ⁇ 8, 11, 14. The fed fatty acid can be detected in large quantities.
  • Fig. 8C for yeasts transformed with the plasmid pYES-D5Des (OI_2).
  • OI_2 yeasts transformed with the plasmid pYES-D5Des
  • an additional fatty acid can be detected in the yeasts with pYES-D5Des (OI_2), which must be due to the activity of D5Des (OI_2).
  • D5Des (OI_2) can be characterized as ⁇ 5-desaturase.
  • D5Des_2 (Ol) SEQ ID 24 was functionally expressed and possesses desaturase activity. From the fed fatty acid, D5Des_2 (Ol) can be characterized as ⁇ 5-desaturase, i. C20 fatty acids with a ⁇ 8 double bond are specifically dehydrogenated at the ⁇ 5 position.
  • D12Des (OI) SEQ ID 18 To determine the activity and substrate specificity of D12Des (OI) SEQ ID 18, various fatty acids were fed (Table 8). The lined substrates are to be detected in large quantities in all transgenic yeasts. The transgenic yeasts show the synthesis of new fatty acids, the products of the D12Des (OI) reaction. This means that the gene D12Des (OI) has been functionally expressed.
  • Table 8 Feeding / conversion of various fatty acids by D12Des (OI).
  • FIG. 9 shows the chromatograms of the individual experiments.
  • yeasts transformed with pYES were analyzed in Fig. 9A without addition of fatty acids.
  • yeasts transformed with pYES-D12Des (OI) were analyzed.
  • an additional fatty acid can be detected in the yeasts with pYES-D12Des (OI), which must be due to the activity of the D12Des (OI).
  • D12Des (OI) can be characterized as ⁇ 12-desaturase.
  • D12Des (OI) SEQ ID 18 was functionally expressed and possesses desaturase activity. From the fatty acid spectrum, D12Des (OI) can be characterized as ⁇ 12-desaturase, i. C18 fatty acids with a ⁇ 9 double bond are specifically dehydrogenated at the ⁇ 12 position.
  • D5Des (OI) SEQ ID 26 To determine the activity and substrate specificity of D5Des (OI) SEQ ID 26, various fatty acids were fed (Table 9). The lined substrates are to be detected in large quantities in all transgenic yeasts. The transgenic yeasts show the synthesis of new fatty acids, the products of the D5Des (OI) reaction. This means that the gene D5Des (OI) has been functionally expressed.
  • FIG. 10 shows the gas chromatographic analysis of yeast feeding experiments. After expression of pYes-d5Des (OI_1) in yeast strain InvSc without addition of fatty acids ( Figure 10A), no conversion of the fatty acids present was found.
  • pYes-d5Des (OI_1) expression in yeast strain InvSc after addition of fatty acid 20: 3n-6 (B) leads to the specific conversion of 20: 3n-6 to 20: 4n-6 (arachidonic acid) and expression of pYes-d5Des (OI_1 ) in yeast strain InvSc after addition of the fatty acid 20: 4n-3 (C) for specific conversion of 20: 4n-3 to 20: 5n-3 (eicosapentaenoic acid).
  • the specific incorporation of d5 double bonds into the fed fatty acids shows the d5-desaturase activity of d5Des (OI).
  • D5Des (OI) SEQ ID 26 was functionally expressed and has desaturase activity.
  • D5Des can be characterized as ⁇ 5-desaturase, i. C20 fatty acids with a ⁇ 8 double bond are bound specifically to the ⁇ 5-

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Animal Husbandry (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Insects & Arthropods (AREA)
  • Botany (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne des polynucléotides d'Ostreococcus lucimarinus qui codent pour des désaturases et des élongases et qui peuvent être utilisés pour la production par voie recombinante d'acides gras polyinsaturés. L'invention concerne en outre des vecteurs, des cellules hôtes et des organismes transgéniques non humains qui contiennent ces polynucléotides, ainsi que les polypeptides codés par ces derniers. Enfin, l'invention concerne également des procédés de production des acides gras polyinsaturés et de compositions à bases d'huiles, de lipides et d'acides gras.
EP07820931A 2006-10-06 2007-10-04 Procédé de production d'acides gras polyinsaturés dans des organismes transgéniques Withdrawn EP2054509A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP15201721.6A EP3066934A1 (fr) 2006-10-06 2007-10-04 Procede de fabrication de plusieurs acides gras insatures dans des organismes transgeniques
EP07820931A EP2054509A2 (fr) 2006-10-06 2007-10-04 Procédé de production d'acides gras polyinsaturés dans des organismes transgéniques
PL09175508T PL2177605T3 (pl) 2006-10-06 2007-10-04 Delta-5 desaturazy i sposób wytwarzania wielokrotnie nienasyconych kwasów tłuszczowych w organizmach transgenicznych innych niż człowiek
EP09175509.0A EP2182056B1 (fr) 2006-10-06 2007-10-04 Procédé de production d'acides gras polyinsaturés dans des organismes transgéniques non-humains
EP09175508.2A EP2177605B1 (fr) 2006-10-06 2007-10-04 Delta-5 deasturase et procédé de production d'acides gras polyinstaurés dans des organimes transgéniques non-humains

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06121888 2006-10-06
PCT/EP2007/060554 WO2008040787A2 (fr) 2006-10-06 2007-10-04 Procédé de production d'acides gras polyinsaturés dans des organismes transgéniques
EP07820931A EP2054509A2 (fr) 2006-10-06 2007-10-04 Procédé de production d'acides gras polyinsaturés dans des organismes transgéniques

Related Child Applications (3)

Application Number Title Priority Date Filing Date
EP15201721.6A Division EP3066934A1 (fr) 2006-10-06 2007-10-04 Procede de fabrication de plusieurs acides gras insatures dans des organismes transgeniques
EP09175509.0A Division EP2182056B1 (fr) 2006-10-06 2007-10-04 Procédé de production d'acides gras polyinsaturés dans des organismes transgéniques non-humains
EP09175508.2A Division EP2177605B1 (fr) 2006-10-06 2007-10-04 Delta-5 deasturase et procédé de production d'acides gras polyinstaurés dans des organimes transgéniques non-humains

Publications (1)

Publication Number Publication Date
EP2054509A2 true EP2054509A2 (fr) 2009-05-06

Family

ID=38857863

Family Applications (4)

Application Number Title Priority Date Filing Date
EP09175509.0A Not-in-force EP2182056B1 (fr) 2006-10-06 2007-10-04 Procédé de production d'acides gras polyinsaturés dans des organismes transgéniques non-humains
EP07820931A Withdrawn EP2054509A2 (fr) 2006-10-06 2007-10-04 Procédé de production d'acides gras polyinsaturés dans des organismes transgéniques
EP15201721.6A Ceased EP3066934A1 (fr) 2006-10-06 2007-10-04 Procede de fabrication de plusieurs acides gras insatures dans des organismes transgeniques
EP09175508.2A Not-in-force EP2177605B1 (fr) 2006-10-06 2007-10-04 Delta-5 deasturase et procédé de production d'acides gras polyinstaurés dans des organimes transgéniques non-humains

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP09175509.0A Not-in-force EP2182056B1 (fr) 2006-10-06 2007-10-04 Procédé de production d'acides gras polyinsaturés dans des organismes transgéniques non-humains

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP15201721.6A Ceased EP3066934A1 (fr) 2006-10-06 2007-10-04 Procede de fabrication de plusieurs acides gras insatures dans des organismes transgeniques
EP09175508.2A Not-in-force EP2177605B1 (fr) 2006-10-06 2007-10-04 Delta-5 deasturase et procédé de production d'acides gras polyinstaurés dans des organimes transgéniques non-humains

Country Status (7)

Country Link
US (5) US8710299B2 (fr)
EP (4) EP2182056B1 (fr)
AU (1) AU2007304229B2 (fr)
CA (2) CA2847007C (fr)
ES (1) ES2531391T3 (fr)
PL (1) PL2177605T3 (fr)
WO (1) WO2008040787A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1756280T3 (en) 2004-04-22 2015-02-02 Commw Scient Ind Res Org SYNTHESIS OF CHAIN, polyunsaturated fatty acids BY RECOMBINANT CELLS
CA3056110C (fr) 2004-04-22 2020-07-14 Surinder Pal Singh Synthese d'acides gras polyinsatures a chaine longue par des cellules de recombinaison
CN101578363A (zh) 2006-08-29 2009-11-11 联邦科学技术研究组织 脂肪酸的合成
JP5323715B2 (ja) * 2006-11-30 2013-10-23 ビーエーエスエフ ソシエタス・ヨーロピア １−ビニル−２−ピロリジノンコポリマーを含む農薬製剤
WO2009130291A2 (fr) 2008-04-25 2009-10-29 Basf Plant Science Gmbh Huile végétale de graines
EP2826864B1 (fr) 2008-07-01 2018-04-18 BASF Plant Science GmbH Promoteurs dérivés de brassica napus pour l'expression génique spécifique de semences
AU2015224521B2 (en) * 2008-11-18 2017-09-14 Commonwealth Scientific And Industrial Research Organisation Enzymes and methods for producing omega-3 fatty acids
NO2358882T3 (fr) 2008-11-18 2017-12-23
EP2430166A1 (fr) 2009-05-13 2012-03-21 BASF Plant Science Company GmbH Acyltransférases et leurs utilisations dans la production d'acide gras
EP2440662B1 (fr) 2009-06-08 2018-08-01 BASF Plant Science Company GmbH Nouveaux composants de l'allongement des acides gras et leur utilisation
US9493520B2 (en) 2009-07-17 2016-11-15 Basf Plant Science Company Gmbh Fatty acid desaturases and elongases and uses thereof
JP2013502914A (ja) 2009-08-31 2013-01-31 ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー 多価不飽和脂肪酸合成の増強を促進する植物の種子特異的遺伝子発現を増強する調節核酸分子
WO2011064181A1 (fr) 2009-11-24 2011-06-03 Basf Plant Science Company Gmbh Nouvelle désaturase d'acides gras et ses utilisations
US9347049B2 (en) 2009-11-24 2016-05-24 Basf Plant Science Company Gmbh Fatty acid elongase and uses thereof
NO2585603T3 (fr) 2010-06-25 2018-05-19
US9458477B2 (en) 2010-10-21 2016-10-04 Basf Plant Science Company Gmbh Fatty acid desaturases, elongases, elongation components and uses thereof
BR112014025265A2 (pt) * 2012-04-12 2017-07-11 Rothamsted Res Ltd produção de ácidos graxos poli-insaturados ômega-3 de cadeia longa
PL2861059T3 (pl) 2012-06-15 2017-10-31 Commw Scient Ind Res Org Wytwarzanie długołańcuchowych wielonienasyconych kwasów tłuszczowych w komórkach roślinnych
CA2879154A1 (fr) 2012-08-03 2014-02-06 Basf Plant Science Company Gmbh Nouvelles enzymes, composants enzymatiques et leurs utilisations
WO2015001505A2 (fr) 2013-07-05 2015-01-08 Basf Plant Science Company Gmbh Éléments capables de renforcer l'expression ou l'activité génique
US10329541B2 (en) 2013-12-17 2019-06-25 Basf Plant Science Company Gmbh Methods for conversion of the substrate specificity of desaturases
NZ721036A (en) 2013-12-18 2023-07-28 Grains Res & Dev Corp Lipid comprising long chain polyunsaturated fatty acids
PH12016502586B1 (en) 2014-06-27 2023-07-19 Commw Scient Ind Res Org Lipid comprising docosapentaenoic acid
US9649272B2 (en) 2014-10-13 2017-05-16 L'oréal Latex nail compositions having low amounts of photo-initiator
US9820931B2 (en) 2014-10-13 2017-11-21 L'oreal Latex nail compositions having low amounts of photo-initiator
US9636293B2 (en) 2014-10-13 2017-05-02 L'oréal Latex nail compositions having low amounts of photo-initiator

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352605A (en) 1983-01-17 1994-10-04 Monsanto Company Chimeric genes for transforming plant cells using viral promoters
EP0131623B2 (fr) 1983-01-17 1999-07-28 Monsanto Company Genes chimeriques appropries a l'expression dans des cellules vegetales
US5504200A (en) 1983-04-15 1996-04-02 Mycogen Plant Science, Inc. Plant gene expression
US5420034A (en) 1986-07-31 1995-05-30 Calgene, Inc. Seed-specific transcriptional regulation
DK162399C (da) 1986-01-28 1992-03-23 Danisco Fremgangsmaade til ekspression af gener i baelgplanteceller, dna-fragment, rekombineret dna-fragment samt plasmid til brug ved udoevelsen af fremgangsmaaden
US4962028A (en) 1986-07-09 1990-10-09 Dna Plant Technology Corporation Plant promotors
US5110728A (en) 1986-07-31 1992-05-05 Calgene, Inc. Acyl carrier protein - DNA sequence and synthesis
US5614395A (en) 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
NZ228320A (en) 1988-03-29 1991-06-25 Du Pont Nucleic acid promoter fragments of the promoter region homologous to the em gene of wheat, dna constructs therefrom and plants thereof
CA1341467C (fr) 1988-07-29 2004-12-07 John C. Rogers Production de polypeptides d'interet commercial a l'aide d'endosperme genetiquement modifie
DE3843628A1 (de) 1988-12-21 1990-07-05 Inst Genbiologische Forschung Wundinduzierbare und kartoffelknollenspezifische transkriptionale regulation
EP0388186A1 (fr) 1989-03-17 1990-09-19 E.I. Du Pont De Nemours And Company Régulation externe de l'expression de gènes
ATE241007T1 (de) 1990-03-16 2003-06-15 Calgene Llc Dnas, die für pflanzliche desaturasen kodieren und deren anwendungen
JPH04506155A (ja) 1990-03-16 1992-10-29 カルジーン，インコーポレイティド 初期種子形成において優先的に発現される新規配列およびそれに関連する方法
US5187267A (en) 1990-06-19 1993-02-16 Calgene, Inc. Plant proteins, promoters, coding sequences and use
WO1993020216A1 (fr) 1991-02-22 1993-10-14 University Technologies International, Inc. Elements cis de proteines des corps oleiferes, servant de signaux de regulation
CA2106960C (fr) 1991-04-09 2005-03-08 Jacqueline De Silva Stimulation de croissance regulant la biosynthese des lipides dans les semences
PH31293A (en) 1991-10-10 1998-07-06 Rhone Poulenc Agrochimie Production of y-linolenic acid by a delta6-desaturage.
US5614393A (en) 1991-10-10 1997-03-25 Rhone-Poulenc Agrochimie Production of γ-linolenic acid by a Δ6-desaturase
CA2124673C (fr) 1991-12-04 2008-08-05 John Browse Genes de desaturase d'acides gras de plantes
CA2084348A1 (fr) 1991-12-31 1993-07-01 David F. Hildebrand Modification de la synthese des acides gras dans des tissus vegetaux transgeniques au moyen d'une d9-desaturase
DE4208050A1 (de) 1992-03-13 1993-09-23 Bayer Ag Azolylmethyl-fluorcyclopropyl-derivate
CA2092069A1 (fr) 1992-03-27 1993-09-28 Asako Iida Plasmide d'expression pour semence
PT637339E (pt) 1992-04-13 2002-03-28 Syngenta Ltd Construcoes de adn e plantas que as incorporam
JPH0662870A (ja) 1992-08-18 1994-03-08 Mitsui Giyousai Shokubutsu Bio Kenkyusho:Kk 大豆ホスホエノールピルビン酸カルボキシラーゼ遺伝子のプロモーター領域及び５’非翻訳領域
DK0668919T3 (da) 1992-11-17 2003-09-15 Du Pont Gener for mikorsomale delta-12-fedtsyredesaturaser og beslægtede enzymer fra planter
JPH08506490A (ja) 1993-02-05 1996-07-16 モンサント・カンパニー 植物中の改変リノレン酸及びリノール酸含量
GB9324707D0 (en) 1993-12-02 1994-01-19 Olsen Odd Arne Promoter
DE733059T1 (de) 1993-12-09 1997-08-28 Univ Jefferson Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
US5576198A (en) 1993-12-14 1996-11-19 Calgene, Inc. Controlled expression of transgenic constructs in plant plastids
BR9408435A (pt) 1993-12-28 1997-08-05 Kirin Brewery Gene para dessaturase de ácido graxo vetor contendo o dito gene planta transformada com o dito gene e processo para criar a dita planta
GB9403512D0 (en) 1994-02-24 1994-04-13 Olsen Odd Arne Promoter
US6310194B1 (en) 1994-09-26 2001-10-30 Carnegie Institution Of Washington Plant fatty acid hydroxylases
GB9421286D0 (en) 1994-10-21 1994-12-07 Danisco Promoter
US5689040A (en) 1995-02-23 1997-11-18 The Regents Of The University Of California Plant promoter sequences useful for gene expression in seeds and seedlings
JP4424756B2 (ja) 1995-07-05 2010-03-03 サッポロビール株式会社 組織特異的プロモーターを用いたトランスジェニック植物およびその作出方法
DE69632403T2 (de) 1995-08-10 2005-05-19 Rutgers University Zellkern-codiertes transkriptionssystem plastiden höherer pflanzen
AU1293297A (en) 1995-12-14 1997-07-03 Cargill Incorporated Plants having mutant sequences that confer altered fatty acid profiles
EP0794250A1 (fr) 1996-03-04 1997-09-10 Soremartec S.A. Isolation et séquence d'un gène FAd2-N du noisetier
US5731181A (en) 1996-06-17 1998-03-24 Thomas Jefferson University Chimeric mutational vectors having non-natural nucleotides
DE19626564A1 (de) 1996-07-03 1998-01-08 Hoechst Ag Genetische Transformation von Ciliatenzellen durch Microcarrier-Bombardement mit DNA beladenen Goldpartikeln
US5981841A (en) 1996-08-30 1999-11-09 Monsanto Company Early seed 5' regulatory sequence
US5977436A (en) 1997-04-09 1999-11-02 Rhone Poulenc Agrochimie Oleosin 5' regulatory region for the modification of plant seed lipid composition
US5972664A (en) 1997-04-11 1999-10-26 Abbott Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
NZ337459A (en) 1997-04-11 2000-07-28 Abbott Lab Nucleic acid construct in plants and dietary supplement
US5968809A (en) 1997-04-11 1999-10-19 Abbot Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
AR013633A1 (es) 1997-04-11 2001-01-10 Calgene Llc METODO PARA LA ALTERACIoN DE LA COMPOSICIoN DE ÁCIDOS GRASOS DE CADENA MEDIA EN SEMILLAS VEGETALES QUE EXPRESAN UNA TIOESTERASA QUE PREFIERE CADENA MEDIA VEGETAL HETERoLOGA.
JP2001518305A (ja) 1997-09-30 2001-10-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 植物種子におけるタンパク質製造
GB9724783D0 (en) 1997-11-24 1998-01-21 Inst Arable Crops Research Novel polypeptides
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU747486B2 (en) 1998-03-11 2002-05-16 Novartis Ag Novel plant plastid promoter sequence
US6010907A (en) 1998-05-12 2000-01-04 Kimeragen, Inc. Eukaryotic use of non-chimeric mutational vectors
US6004804A (en) 1998-05-12 1999-12-21 Kimeragen, Inc. Non-chimeric mutational vectors
WO1999064616A2 (fr) 1998-06-12 1999-12-16 Abbott Laboratories Acides gras polyinsatures dans des plantes
US6403349B1 (en) 1998-09-02 2002-06-11 Abbott Laboratories Elongase gene and uses thereof
US6677145B2 (en) 1998-09-02 2004-01-13 Abbott Laboratories Elongase genes and uses thereof
EP1121150A4 (fr) 1998-10-09 2003-06-04 Merck & Co Inc Desaturase d'acide gras delta 6
US6271360B1 (en) 1999-08-27 2001-08-07 Valigen (Us), Inc. Single-stranded oligodeoxynucleotide mutational vectors
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
EE200200443A (et) 2000-02-09 2003-12-15 Basf Aktiengesellschaft Uus elongaasigeen ning polüküllastumata rasvhapete saamise meetod
EP1341920A2 (fr) 2000-11-29 2003-09-10 Xenon Genetics, Inc. Genes humains de l'elongase et leurs utilisations
DE10102338A1 (de) 2001-01-19 2002-07-25 Basf Plant Science Gmbh Verfahren zur Expression von Biosynthesegenen in pflanzlichen Samen unter Verwendung von neuen multiplen Expressionskonstrukten
DE10102337A1 (de) 2001-01-19 2002-07-25 Basf Plant Science Gmbh Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren, neue Biosynthesegene sowie neue pflanzliche Expressionskonstrukte
GB0107510D0 (en) 2001-03-26 2001-05-16 Univ Bristol New elongase gene and a process for the production of -9-polyunsaturated fatty acids
DE10219203A1 (de) 2002-04-29 2003-11-13 Basf Plant Science Gmbh Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren in Pflanzen
ES2713548T3 (es) * 2003-08-01 2019-05-22 Basf Plant Science Gmbh Procedimiento para la producción de ácidos grasos poliinsaturados en organismos transgénicos
WO2005083053A2 (fr) 2004-02-27 2005-09-09 Basf Plant Science Gmbh Procede pour produire des acides gras $g(v)-3 insatures dans des organismes transgeniques
DE102004063326A1 (de) * 2004-12-23 2006-07-06 Basf Plant Science Gmbh Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren in transgenen Organismen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008040787A2 *

Also Published As

Publication number Publication date
EP2182056A1 (fr) 2010-05-05
EP2182056B1 (fr) 2015-12-23
CA2665336C (fr) 2016-01-05
US20130340103A1 (en) 2013-12-19
ES2531391T3 (es) 2015-03-13
CA2847007C (fr) 2016-11-08
WO2008040787A3 (fr) 2008-06-12
US8710299B2 (en) 2014-04-29
WO2008040787A2 (fr) 2008-04-10
US9382529B2 (en) 2016-07-05
US20160304841A1 (en) 2016-10-20
EP2177605B1 (fr) 2014-12-10
AU2007304229A1 (en) 2008-04-10
US20190225948A1 (en) 2019-07-25
CA2847007A1 (fr) 2008-04-10
US20220056423A1 (en) 2022-02-24
EP2177605A1 (fr) 2010-04-21
CA2665336A1 (fr) 2008-04-10
US10308914B2 (en) 2019-06-04
US11168308B2 (en) 2021-11-09
PL2177605T3 (pl) 2015-05-29
AU2007304229B2 (en) 2013-09-19
US20100088776A1 (en) 2010-04-08
EP3066934A1 (fr) 2016-09-14

Similar Documents

Publication Publication Date Title
EP2182056B1 (fr) Procédé de production d'acides gras polyinsaturés dans des organismes transgéniques non-humains
EP2166067B1 (fr) Procédé de production d'acides gras polyinsaturés chez des organismes transgéniques
EP2176433B1 (fr) Désaturases et procédés de production d'acides gras polyinsaturés dans des organismes transgéniques
EP1720988B1 (fr) PROCEDE POUR PRODUIRE DES ACIDES GRAS omega-3 INSATURES DANS DES ORGANISMES TRANSGENIQUES
EP2176416B1 (fr) Élongases et procédés de production d'acides gras polyinsaturés dans des organismes transgéniques
EP1769074A2 (fr) Procédé permettant d'augmenter la teneur d'organismes transgéniques en acides gras à chaine longue polyinsatures
EP1831377A1 (fr) Procede de production d'acides gras polyinsatures dans des organismes transgeniques
DE112009003708T5 (de) Desaturasen und Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren in transgenenOrganismen
WO2008104559A1 (fr) Procédé de production d'acides gras polyinsaturés dans des organismes transgéniques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090323

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17Q First examination report despatched

Effective date: 20090626

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100108